INBP Integrated BioPharma Inc (QX)

 

 

 

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

 

Certain statements in this Annual Report on Form 10-K may constitute forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Private Securities Litigation Reform Act of 1995 (the “PSLRA”) or in releases made by the Securities and Exchange Commission (“SEC”), all as may be amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of Integrated BioPharma, Inc. and its subsidiaries (collectively, the “Company”) or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by the Company; changes in industry capacity; pressure on prices from competition or from purchasers of the Company's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to the Company; availability of qualified personnel; the loss of any significant customers or suppliers; the impact of the war in Ukraine; the tightened labor markets and inflation; and other factors both referenced and not referenced in this Annual Report. Statements that are not historical fact are forward-looking statements. Forward looking-statements can be identified by, among other things, the use of forward-looking language, such as the words “plan”, “believe”, “expect”, “anticipate”, “intend”, “estimate”, “project”, “may”, “will”, “would”, “could”, “should”, “seeks”, or “scheduled to”, or other similar words, or the negative of these terms or other variations of these terms or comparable language, or by discussion of strategy or intentions. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act and the PSLRA with the intention of obtaining the benefits of the “safe harbor” provisions of such laws. The Company cautions investors that any forward-looking statements made by the Company are not guarantees or indicative of future performance. Important assumptions and other important factors that could cause actual results to differ materially from those forward-looking statements with respect to the Company include, but are not limited to, the risks and uncertainties affecting their businesses described in Item 1A of this Annual Report on Form 10-K and in other filings by the Company with the SEC. 

 

Although the Company believes that its plans, intentions and expectations reflected in or suggested by such forward-looking statements are reasonable, actual results could differ materially from a projection or assumption in any of its forward-looking statements. The Company’s future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties. The forward-looking statements contained in this Annual Report on Form 10-K are made only as of the date hereof and the Company does not have or undertake any obligation to update or revise any forward-looking statements whether as a result of new information, subsequent events or otherwise, unless otherwise required by law.

 

 

PART I

Item 1. Description of Business

 

General

 

Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products.  The Company’s customers are located primarily in the United States and Luxembourg. The Company was originally incorporated in the state of Delaware on August 31, 1995 under the name Chem International, Inc., on December 5, 2000, changed its name to Integrated Health Technologies, Inc. and, on January 29, 2003, changed its name to Integrated BioPharma, Inc.  The Company restated its certificate of incorporation in Delaware in June 2006.  The Company continues to do business as Chem International, Inc. with certain of its customers and certain vendors.

 

The Company’s business segments include: (a) Contract Manufacturing operated by Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers and (b) Other Nutraceutical Businesses which includes the operations of (i) AgroLabs, Inc. (“AgroLabs”), which distributed healthful nutritional products for sale through major mass market, grocery and drug and vitamin retailers under the following brands: Peaceful Sleep, and Wheatgrass and other products introduced into the market using the AgroLabs name (these are referred to as our branded products); (ii) The Vitamin Factory (the “Vitamin Factory”), which sells private label MDC products, as well as our AgroLabs products, through the Internet,  (iii) IHT Health Products, Inc. (“IHT”) a distributor of fine natural botanicals, including multi minerals produced under a license agreement, (iv) MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfilment services and (v) Chem International, Inc., a distributor of certain raw materials for DSM Nutritional Products LLC.  The Vitamin Factory had no products available for sale and AgroLabs had no sales of its branded products in each of the fiscal years ended June 30, 2023 and 2022.

 

Significant Revenues from Major Customers

 

In the fiscal years ended June 30, 2023 and 2022, a significant portion of our consolidated net sales, approximately 89% and 90%, respectively, were concentrated among two customers, Life Extension Quality Supplements and Vitamins, Inc. (“Life Extension”) and Herbalife Nutrition LTD (“Herbalife”), both customers in our Contract Manufacturing Segment.  Life Extension and Herbalife represented approximately 70% and 24% and 67% and 26%, respectively, of our Contract Manufacturing Segment’s net sales in the fiscal years ended June 30, 2023 and 2022, respectively.  Thermosource Tooling and Manufacturing, HotPack Global Inc. and ThermoFisher Scientific (customers of our Other Nutraceutical Businesses Segment), while not significant customers of our consolidated net sales, represented approximately 56%, 16% and 9% and 40%, 1%  and 19%, respectively, of the Other Nutraceutical Businesses net sales in the fiscal years ended June 30, 2023 and 2022, respectively. The loss of any of these customers could have a significant adverse impact on our financial condition and results of operations.

 

Raw Materials

 

The principal raw materials used in the manufacturing process in the Company’s business are natural and synthetic vitamins, minerals, herbs, related nutritional supplements, vegetable and gelatin capsules, coating materials, organic and natural fruit extracts, fruit juices and the necessary components for packaging the finished products. The raw materials are available from numerous sources within the United States and abroad. The vegetable and gelatin capsules, coating materials and packaging materials are similarly widely available. The Company generally purchases its raw materials, on a purchase order basis, without long-term commitments in each of its operating segments. We have one principal supplier for our Other Nutraceutical Businesses segment, DSM Nutritional Products LLC and several suppliers in our Contract Manufacturing Segment.

 

Development and Supply Agreement

 

Effective July 15, 2009, the Company entered into development and supply agreements with Herbalife International of America, Inc. and Herbalife International of Luxembourg S.à.R.L, subsidiaries of Herbalife, pursuant to which the Company develops, manufactures and supplies certain nutritional products to Herbalife. This agreement is in the process of being extended through December 31, 2025. This agreement does not, however, obligate the Company to supply any particular amount of goods to Herbalife, nor does it obligate Herbalife to commit to a minimum order, if any. In its ordinary course of business, the Company enters into similar agreements with other customers in connection with its contract manufacturing business.

 

 

Seasonality

 

The nutraceutical business tends to be seasonal. We have found that in our first fiscal quarter ending on September 30^th of each year, orders for our branded proprietary nutraceutical products usually slow (absent the addition of new customers or a new product launch with a significant first time order), as buyers in various markets may have purchased sufficient inventory to carry them through the summer months. Conversely, in our second fiscal quarter, ending on December 31^st of each year, orders for our products increase as the demand for our branded nutraceutical products, as well as sales orders from our customers in our contract manufacturing segment, seem to increase in late December to early January as consumers become health conscious as they enter the new year.

 

The Company believes that there are other non-seasonal factors that also may influence the variability of quarterly results including, but not limited to, general economic and industry conditions that affect consumer spending, changing consumer demands and current news on nutritional supplements. Accordingly, a comparison of the Company’s results of operations from consecutive periods is not necessarily meaningful, and the Company’s results of operations for any period are not necessarily indicative of future periods.

 

Government Regulations

 

The manufacturing, processing, formulation, packaging, labeling and advertising of our products are subject to regulation by a number of federal agencies, including the Food and Drug Administration (“FDA”), the Federal Trade Commission (“FTC”), the United States Postal Service, the Consumer Product Safety Commission and the United States Department of Agriculture. Our activities are also regulated by various state and local agencies in states where our products are sold. The FDA is primarily responsible for the regulation of the manufacturing, labeling and sale of our products. The operation of our vitamin manufacturing facility is subject to regulation by the FDA as a dietary supplement manufacturing facility. The United States Postal Service and the FTC regulate advertising claims with respect to the Company’s products. In addition, we manufacture and market certain of our products in compliance with the guidelines promulgated by the United States Pharmacopoeia Convention, Inc. (“USP”) and other voluntary standards organizations.

 

The Dietary Supplement Health and Education Act of 1994 (“DSHEA”) was enacted on October 25, 1994. The Dietary Supplement Act amends the U.S. Federal Food, Drug and Cosmetic Act (“FFD&CA”) by defining dietary supplements, which include vitamins, minerals, nutritional supplements and herbs, and by providing a regulatory framework to ensure safe, quality dietary supplements and the dissemination of accurate information about such products. The FDA is generally prohibited from regulating the active ingredients in dietary supplements as food additives, or as drugs unless product claims trigger drug status. The DSHEA requires the FDA to regulate dietary supplements so as to guarantee consumer access to beneficial dietary supplements, allowing only truthful and proven claims. Generally, dietary ingredients that were on the market before October 15, 1994 may be sold without FDA pre-approval and without notifying the FDA. However, new dietary ingredients (those not used in dietary supplements marketed before October 15, 1994) require pre-market submission to the FDA of evidence of a history of their safe use, or other evidence establishing that they are reasonably expected to be safe. There can be no assurance that the FDA will accept the evidence of safety for any new dietary ingredient we may decide to use. The FDA’s refusal to accept such evidence could result in regulation of such dietary ingredients as food additives, requiring the FDA pre-approval based on newly conducted, costly safety testing.

 

DSHEA provides for specific nutritional labeling requirements for dietary supplements effective January 1, 1997. The Dietary Supplement Act permits substantiated, truthful and non-misleading statements of nutritional support to be made in labeling, such as statements describing general well-being from consumption of a dietary ingredient or the role of a nutrient or dietary ingredient in affecting or maintaining the structure or function of the body. The FDA requires the Company to notify the FDA of such statements. There can be no assurance that the FDA will not consider particular labeling statements used by us to be drug claims rather than acceptable statements of nutritional support, necessitating approval of a costly new drug application, or re-labeling to delete such statements. It is also possible that the FDA could allege false statements were submitted to it if structure/function claim notifications were either non-existent or so lacking in scientific support as to be plainly false.

 

 

As authorized by DSHEA, the FDA adopted Good Manufacturing Practices (“GMP”) specifically for dietary supplements (21 CFR Part 111). These GMP regulations, which became effective in June 2008, are more detailed than the GMPs that previously applied to dietary supplements and require, among other things, dietary supplements to be prepared, packaged and held in compliance with specific rules, and require quality controls similar to those required by GMP regulations for drugs. We believe our manufacturing and distribution practices comply with these rules.

 

Dietary supplements are also subject to the Nutrition, Labeling and Education Act (“NLEA”), which regulates health claims, ingredient labeling and nutrient content claims characterizing the level of a nutrient in a product. NLEA prohibits the use of any health claim for dietary supplements unless the health claim is supported by significant agreement within the scientific community and is pre-approved by the FDA.

 

In certain markets, including the United States, claims made with respect to dietary supplements may change the regulatory status of our products. For example, in the United States, the FDA could possibly take the position that claims made for some of our products classify those products as new drugs requiring pre-approval by the FDA. The FDA could also place those products within the scope of its over-the-counter (“OTC”) drug regulations and require us to comply with a published FDA OTC monograph. OTC monographs dictate permissible ingredients, appropriate labeling language and require the marketer or supplier of the products to register and file annual drug listing information with the FDA. We do not, at present, sell OTC drug products. If the FDA were to assert that our product claims cause them to be considered new drugs or to fall within the scope of OTC regulations, we would be required to either; file a new drug application, comply with the applicable monographs, or change the claims made in connection with those products.

 

The FTC regulates the marketing practices and advertising of all our products. In recent years, the FTC instituted enforcement actions against several dietary supplement companies for false and misleading marketing practices and advertising of certain products. These enforcement actions have resulted in consent decrees and monetary payments by the companies involved. Under FTC standards, the dissemination of any false advertising constitutes an unfair or deceptive act or practice actionable under Section 45 of the Fair Trade Commission Act and a false advertisement actionable under Section 52 of that Act. A false advertisement is one that is “misleading in a material respect.” In determining whether an advertisement or labeling information is misleading in a material respect, the FTC determines not only whether overt and implied representations are false but also whether the advertisement fails to reveal material facts. Under the FTC’s standards, any health benefit representation made in advertising must be backed by “competent and reliable scientific evidence” by which the FTC means: “tests, analyses, research studies, or other evidence based upon the expertise of professionals in the relevant area, that have been conducted and evaluated in an objective manner by persons qualified to do so, using procedures generally accepted by the profession to yield accurate and reliable results.”

 

The FTC has increased its review of the use of the type of testimonials that may be used to market our products. The FTC requires competent and reliable evidence substantiating claims and testimonials at the time that such claims of health benefit are first made. The failure to have this evidence when product claims are first made violates the Federal Trade Commission Act. Although the FTC has never threatened an enforcement action against the Company for the advertising of its products, there can be no assurance that the FTC will not question the advertising for our products in the future.

 

We believe we are currently in compliance with all applicable government regulations. We cannot predict what new legislation or regulations governing our operations will be enacted by legislative bodies or promulgated by agencies that regulate its activities. The FDA is expected to increase its enforcement activity against dietary supplements that it considers to be in violation of FFD&CA. In particular, the FDA is increasing its enforcement of DSHEA provisions. Those activities will be enhanced by the appropriation for increased FDA budgets for dietary supplement regulation enforcement.

 

 

We believe we may become subject to additional laws or regulations administered by the FDA or other federal, state, or foreign regulatory authorities. We also believe the laws or regulations which are considered favorable may be repealed, or more stringent interpretations of current laws or regulations may be implemented. Any or all of such requirements could be a burden to us. Future regulations could require us to:

 

●    change the way we conduct business;

●    use expanded or different labeling;

●    recall, reformulate or discontinue certain products;

●    keep additional records;

●    increase the available documentation of the properties of its products; and/or

●    increase the scientific proof of product ingredients, safety, and/or usefulness.

 

Competition

 

The business of manufacturing, distributing and marketing vitamins and nutritional supplements is highly competitive. Many of our competitors are substantially larger and have greater financial resources with which to manufacture and market their products. In particular, the retail segment is highly competitive. Many direct marketers not only focus on selling their own branded products, but offer national brands at discounts as well. Many competitors have established brand names recognizable to consumers. In addition, major pharmaceutical companies offer nationally advertised multivitamin products.

 

Many of our competitors in the retailing segment have the financial resources to advertise freely, to promote sales and to produce sophisticated catalogs and websites. In many cases, such competitors are able to offer price incentives for retail purchasers and to offer participation in frequent buyers programs. Some retail competitors also manufacture their own products whereby they have the ability and financial incentive to sell their own product.

 

We intend to compete by stressing the quality of our manufactured products, providing prompt service, competitive pricing of products in our marketing segment and by focusing on niche products in international retail markets.

 

Research and Development Activities

 

We do not conduct any significant research and development activities.

 

Environmental Compliance

 

We are subject to regulation under Federal, state and local environmental laws. While we believe we are in material compliance with applicable environmental laws, continued compliance may require substantial capital expenditures. We have not incurred any major costs for any environmental compliance during the years ended June 30, 2023 and 2022.

 

 

 

 

Employees

 

As of September 15, 2023, we had approximately 141 full time employees, including 106 who are members of the local unit of the Teamsters Union and are covered by a collective bargaining agreement which expires on August 31, 2027.  The remaining 35 employees, not covered by a collective bargaining agreement, consist of approximately 15 administrative and professional personnel, 12 laboratory and quality assurance personnel, 3 sales and marketing personnel and 5 production and shipping personnel. We consider our relations with our employees to be good.

 

In December 2022, we entered into an agreement with a Professional Employer Organization (“PEO”) and terminated our agreement with the previous PEO. The PEO agreements established a three-way relationship between our non-union employees, the PEO and us. We and the PEO are co-employers of our non-union employees. The PEO has taken responsibility for our Human Resources administration and compliance, which allows us to continue to exercise control over our business while accessing quality employee benefits. We have been using PEOs since January 2007.

 

 

Available Information

 

We file annual, quarterly and current reports, proxy statements and other information with the SEC. These filings are available to the public via the Internet at the SEC's website located at http://www.sec.gov.

 

Our website is located at ir.ibiopharma.com. You may request a copy of our filings with the SEC (excluding exhibits) at no cost by writing or telephoning us at the following address or telephone number:

 

Integrated BioPharma, Inc.

225 Long Avenue, Bldg. 15

Hillside, New Jersey 07205

Attn: Investor Relations

Tel: 888-319-6962

 

 

 

Item 1A. Risk Factors

 

Please carefully consider the following risk factors which could materially adversely affect our business, financial condition, operating results and cash flows. The risk factors described below are not the only ones we face. Risks and uncertainties not known to us currently, or that we currently deem immaterial, also may materially adversely affect our business, financial condition, operating results and cash flows.

 

Our revenue could decline significantly if we lose one or more of our most significant customers, which could have a significant adverse impact on us.

 

A significant portion of our revenues are concentrated among four customers, Life Extension, Herbalife (customers in our Contract Manufacturing Segment), and Thermosource Tooling and Manufacturing and Hotpack Global, Inc. (customers of our Other Nutraceutical Businesses Segment).  In the fiscal years ended June 30, 2023 and 2022, approximately 89% and 90% of our consolidated net sales, respectively, were derived from the two major customers in our Contract Manufacturing Segment.  The loss of any of these customers could have a significant adverse impact on our financial condition and results of operations.

 

Supply chain disruptions resulting from geo-political events could have an impact on our financial results and ability to timely ship products to our customers.

 

These issues first arose as result of the COVID-19 pandemic and other geo-political events.  Transportation, in general, continues to be an issue in the delay of receiving raw materials and our ability to meet promised delivery dates to our customers in the Contract Manufacturing Segment.

 

While we haven’t, to date, seen a significant negative impact in our margins resulting from the geo-political events, we are experiencing a slight negative impact on our margins due to inflation and tightened labor markets. 

 

During the first quarter of calendar 2022, the war in Ukraine affected our customer’s business operations in Ukraine and Russia, resulting in the cancelation of some future orders. The war resulted in the imposition of sanctions by the United States, the United Kingdom and the European Union that affect the cross-border operations of businesses operating in Russia. In addition, many multinational companies ceased or suspended their operations in Russia. Therefore, the ability to continue operations in Russia by our customers is uncertain.  Also, there may be a shortage of Sunflower Oil products in the near future and this may cause delays in production of certain raw materials and may require reformulation of products.

 

We have indebtedness, which may decrease our flexibility, increase our borrowing costs and adversely affect our liquidity.

 

We currently have $11.6 million in senior secured financing (the “Senior Credit Facility”) available under the Loan Agreement, dated as of June 27, 2012 and as amended on May 15, 2019 (the "Amended Loan Agreement"), by and among the Company, MDC, AgroLabs, IHT Health Products, Inc., IHT Properties Corp. (“IHT Properties”), and Vitamin Factory (collectively, the “Borrowers”) and PNC Bank, National Association ("PNC") and $2,623 in operating lease obligations.  As of June 30, 2023, we have no amounts outstanding with PNC under the Senior Credit Facility.

 

Our level of indebtedness can have important consequences. For example, it may require a substantial portion of our cash flow from operations for the payment of principal of, and interest on, our indebtedness and reduce our ability to use our cash flow to fund working capital, capital expenditures and general corporate requirements or to pay dividends; and limit our flexibility to adjust to changing business and market conditions and make us more vulnerable to a downturn in general economic conditions as compared to our competitors.

 

 

 

There are various financial covenants and other restrictions in the Senior Credit Facility.  If we fail to comply with any of these requirements, any related indebtedness (and other unrelated indebtedness) could become due and payable prior to its stated maturity. A default under the Senior Credit Facility may also significantly affect our ability to obtain additional or alternative financing.  For example, PNC's ongoing obligation to extend credit under the Amended Loan Agreement is dependent upon our compliance with these covenants and restrictions.

 

To the extent we draw down additional funds under the Senior Credit Facility, our ability to make scheduled payments or to refinance our obligations with respect to indebtedness will depend on our operating and financial performance, which, in turn, is subject to prevailing economic conditions and to financial, business and other factors beyond our control. Our inability to refinance our indebtedness when necessary or to do so upon attractive terms would materially and adversely affect our liquidity and our ongoing results of operations.

 

Complying with new and existing government regulation, both in the U.S. and abroad, could increase our costs significantly and adversely affect our financial results.

 

The processing, formulation, manufacturing, packaging, labeling, advertising, distribution and sale of our products are subject to regulation by several U.S. federal agencies, including the FDA, the FTC, the Consumer Product Safety Commission, the Department of Agriculture and the EPA, as well as various state, local and international laws and agencies of the localities in which our products are sold. Government regulations may prevent or delay the introduction, or require the reformulation, of our products. Some agencies, such as the FDA or state agencies, could require us to remove a particular product from the market, delay or prevent the import of raw materials for the manufacture of our products, or otherwise disrupt the marketing of our products. Any such government actions would result in additional costs to us, including lost revenues from any additional products that we are required to remove from the market, which additional costs could be material. Any such government actions also could lead to liability, substantial costs and reduced growth prospects. Moreover, there can be no assurance that new laws or regulations imposing more stringent regulatory requirements on the dietary supplement industry will not be enacted or issued. In addition, complying with adverse event reporting requirements imposes additional costs on us, which costs could become significant in the event more demanding reporting requirements are put into place.

 

Additional or more stringent regulations of dietary supplements and other products have been considered from time to time. These developments could require reformulation of certain products to meet new standards, recalls or discontinuance of certain products that cannot be reformulated, additional record-keeping requirements, increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation, adverse event reporting or other new requirements. These developments also could increase our costs significantly. For example, the FDA issued rules which became effective in 2008 that imposed substantial new regulatory requirements for dietary supplements, including GMPs. Congress also passed legislation requiring adverse event reporting and related record keeping which imposed additional costs on us. See Item 1. "Description of Business—Government Regulations" for additional information.

 

We may be exposed to or the target of legal proceedings initiated by regulators or third parties either in the United States or abroad which could increase our costs and adversely affect our reputation, revenues and operating income.

 

In the United States and abroad, non-compliance with relevant legislation can result in regulators bringing administrative or, in some cases, criminal proceedings. As manufacturers of nutraceutical products, our products are regulated by various governments and it is common for regulators to prosecute retailers and manufacturers for non-compliance with legislation governing foodstuffs and medicines. Failures by us or our subsidiaries to comply with applicable legislation could occur from time to time and prosecution for any such violations could have a material adverse effect on our business, results of operations, financial condition and cash flows. Additionally, we are subject, from time to time, to claims by third parties under various legal theories. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on our liquidity, financial condition and cash flows.

 

 

 

We depend on our senior management, the loss of whom would have an adverse effect on us.

 

We presently are dependent upon the executive abilities of our Co-Chief Executive Officers, Christina Kay and Riva Sheppard, our Chief Financial Officer, Dina L. Masi and the Vice President of Operations for Manhattan Drug Company, Inc. Mireille Antinozzi. Our business and operations to date chiefly have been implemented under the direction of these individuals, who presently are, and in the future will be, responsible for the implementation of our anticipated plans and programs. The loss or unavailability of the services of one or more of our principal executives would have an adverse effect on us. We may encounter difficulty in our ability to recruit and ultimately hire any replacement or additional executive officers having similar background, experience and qualifications as those of our current executive officers.

 

We could be the target of a cybersecurity breach which could have an adverse effect on us.

 

A cybersecurity breach could result in the loss or theft of investor data or funds, the inability to access electronic systems, loss or theft of proprietary information or corporate data, disruption of our operations, physical damage to a computer or network system, or costs associated with system repairs. Such incidents could cause the Company to incur regulatory penalties, reputational damage, remediation costs, litigation costs, additional compliance costs, or financial loss. Intentional cybersecurity breaches include: unauthorized access to systems, networks, or devices (such as through “hacking” activity); infection from computer viruses or other malicious software code; and attacks that shut down, disable, slow, or otherwise disrupt operations, business processes, or website access or functionality. In addition, unintentional incidents can occur, such as the inadvertent release of confidential information (possibly resulting in the violation of applicable privacy laws.

 

There is no assurance that we will remain quoted or listed on an active trading market.

 

As of January 22, 2022, the Company’s common stock was upgraded to the OTCQX® Best Market of the OTC Markets Group, Inc. and commenced quotation under the symbol “INBP.” In order to maintain quotation on the OTCQX, the Company will be required to comply with certain minimum qualitative and quantitative requirements, including with respect to corporate governance. There can be no assurances that the Company will be able to comply with these qualitative and quantitative requirements for continued quotation of its common stock on the OTCQX. If the Company doesn’t maintain compliance with the OTCQX rules, the Company’s common stock may resume listing on the OTCQB and holders of the Company’s common stock may find it more difficult to sell their shares.

 

From September 23, 2009 until January 21, 2022, our common stock was quoted on the OTQB. From February 27, 2009 through September 22, 2009, our common stock was quoted on the Pink Sheets. Prior to February 27, 2009, our common stock was listed on the NASDAQ Global Market, and there can be no assurance that we will, in the future, be able to meet all the requirements for reinstatement on that or any other national securities exchange. The delisting of our common stock from the NASDAQ Global Market has adversely affected, and may in the future continue to adversely affect, the liquidity and trading of our common stock.

 

We have entered into several transactions with entities controlled by some of our officers and directors, which could pose a conflict of interest.

 

We have several agreements and arrangements, described in our previous SEC filings and to be described in our proxy statement for our 2023 annual meeting of stockholders, including the lease of real property from Vitamin Realty Associates, L.L.C. (“Vitamin Realty”), the sale of our financial debt securities, and issuance of our common stock, which involved transactions with entities owned, in whole or in part, by  the Estate of the former Executive Chairman and our Co-Chief Executive Officers and other of our significant shareholders and/or directors, who collectively own a majority of our shares of common stock. Although we believe that these transactions were advantageous to us and were on terms no less favorable to us than could have been obtained from unaffiliated third parties, transactions with related parties can potentially pose a conflict of interest.

 

 

 

 

Our Executive Officers and Directors have majority voting power and may take actions that may not be in the best interest of other stockholders, but in their own interest.

 

Collectively, our Executive Officers, Directors and two other significant stockholders, beneficially own approximately 72% of our outstanding shares of common stock as of September 15, 2023. If these stockholders act together, they would be able to exert significant control over our management and affairs since significant corporate transactions require stockholder approval. This concentration of ownership may have the effect of delaying or preventing a change in control and might adversely affect the market price of our common stock. This concentration of ownership may not be in the best interests of all our stockholders.

 

We have a staggered Board of Directors, which could impede an attempt to acquire the Company or remove our management.

 

Our Board of Directors is divided into three classes, each of which serves for a staggered term of three years. This division of our Board of Directors could have the effect of impeding an attempt to take over our company or change or remove management, since only one class will be elected annually. Thus, only approximately one-third of the existing Board of Directors could be replaced at any election of directors.

 

Our product liability insurance may be insufficient to cover possible claims against us.

 

Our company, like other manufacturers, wholesalers and distributors of vitamin and nutritional supplement products, faces an inherent risk of exposure to product liability claims if, among other things, the use or ingestion of our products, results in sickness or injury. We currently maintain a product liability insurance policy that provides a total of $5.0 million of coverage per occurrence and $5.0 million of coverage in the aggregate. However, there can be no assurance that existing or future insurance coverage will be sufficient to cover any possible product liability risks or that such insurance will continue to be available to us on economically feasible terms.

 

Our nutraceutical products are manufactured using various raw materials consisting of vitamins, minerals, herbs, fruit extracts and other ingredients that we regard as safe when taken as recommended by us and that various scientific studies have suggested may provide health benefits. We could be adversely affected if any of our products or any similar products distributed by other companies should prove or be asserted to be harmful to consumers or should scientific studies provide unfavorable findings regarding the effectiveness of our products.

 

We may not be able to obtain raw materials used in certain of our manufactured products.

 

The principal raw materials used in the manufacturing process in the Company’s nutraceutical business are natural and synthetic vitamins, minerals, herbs, related nutritional supplements, vegetable and gelatin capsules, coating materials, fruit extracts, fruit juices and the necessary components for packaging the finished products. The raw materials are available from numerous sources within the United States and abroad. The vegetable and gelatin capsules, coating materials and packaging materials are similarly widely available. We generally purchase our raw materials, on a purchase order basis, without long-term commitments.

 

We have one principal supplier for our Other Nutraceutical Businesses Segment, DSM Nutritional Products LLC and several suppliers in our Contract Manufacturing Segment. If we are unable to maintain our relationships with our suppliers, we may not be able to find alternate sourcing of our raw materials or at the same pricing that we receive from our current suppliers and/or quickly enough to make timely shipments to our customers. This could decrease our sales and/or increase our cost of sales.

 

Current economic conditions may cause a decline in business and consumer spending which could adversely affect our business and financial performance.

 

Our operating results are impacted by the health of the North American economies. Our business and financial performance, including collection of our accounts receivable, recoverability of assets including investments, may be adversely affected by current and future economic conditions, such as a reduction in the availability of credit, financial market volatility, recession, etc. Additionally, we may experience difficulties in scaling our operations to react to economic pressures in the United States.

 

 

We may incur significant professional service fees and other control costs that impact our financial condition.

 

As a publicly traded corporation, we incur certain costs to comply with regulatory requirements. If regulatory requirements were to become more stringent or if controls thought to be effective later fail, we may be forced to make additional expenditures, the amounts of which could be material. Some of our competitors are privately owned so their accounting and control costs can be a competitive disadvantage for us. Should our sales decline or if we are unsuccessful at increasing prices to cover higher expenditures for internal controls, audits, consultants and legal, our costs associated with regulatory compliance will rise as a percentage of sales.

 

Other issues and uncertainties may include:

●    New accounting pronouncements or changes in accounting policies; and

●    Legislation or other governmental action that detrimentally impacts our expenses or reduces sales by adversely affecting our customers.

 

If we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult.

 

If we fail to comply with the rules under the Sarbanes-Oxley Act, related to disclosure controls and procedures, or if we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult. Moreover, effective internal controls are necessary for us to produce reliable financial reports and are important in helping prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock could drop significantly. While we have not identified any material weakness in our internal control over financial reporting, we cannot be certain that material weaknesses or significant deficiencies in our internal controls will not be discovered in the future.

 

We have not paid dividends on our common stock in the past and do not expect to pay dividends on our common stock for the foreseeable future. Any return on investment may be limited to the value of our common stock.

 

We have never paid any cash dividends on our common stock. We expect that any income received from operations will be devoted to our future operations and growth. We do not expect to pay cash dividends on our common stock in the near future. Payment of dividends would depend upon our profitability at the time, cash available for those dividends, and other factors that our board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on an investor’s investment will only occur if our stock price appreciates. Investors in our common stock should not rely on an investment in our company if they require dividend income.

 

A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline and may impair our ability to raise capital in the future.

 

Our common stock is quoted on the OTCQX® Best Market and could be considered “thinly-traded,” meaning that the number of investors interested in purchasing our common stock at or near bid prices at any given time may be relatively small or non-existent. Finance transactions resulting in a large amount of newly issued shares that become readily tradable, or other events that cause current stockholders to sell shares, could place downward pressure on the trading price of our common stock. In addition, the lack of a robust resale market may require a stockholder who desires to sell a large number of shares of common stock to sell the shares in increments over time to mitigate any adverse impact of the sales on the market price of our stock.

 

If our stockholders sell, or the market perceives that our stockholders may sell for various reasons, including the ending of restriction on resale, substantial amounts of our common stock in the public market, including shares issued upon the exercise of outstanding options or warrants, the market price of our common stock could fall. Sales of a substantial number of shares of our common stock may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.

 

Item 1B. Unresolved Staff Comments

 

Not applicable.

 

 

Item 2. Properties

 

Warehouse and office facilities are leased from Vitamin Realty, which is 100% owned by the estate of our former Executive Chairman of the Board, President and major stockholder of the Company and our Co-Chief Executive Officers who are also directors of the Company.  On January 5, 2012, MDC, a wholly-owned subsidiary of the Company, entered into a second amendment of the lease (the “Second Lease Amendment”) with Vitamin Realty for its office and warehouse space in Hillside, New Jersey increasing its rentable square footage from an aggregate of 74,898 square feet to 76,161 square feet and extending the expiration date to January 31, 2026.  On July 15, 2022, MDC entered into a third amendment of the lease (the “Third Lease Amendment”) with Vitamin Realty, increasing its rentable square footage to 116,175.  This Third Lease Amendment provides for minimum annual rental payments of $842, plus increases in real estate taxes and the building operating expenses allocation percentage and was effective as of July 1, 2022.

 

We also own a 40,000 square foot manufacturing facility in Hillside, New Jersey. The space is utilized for MDC’s tablet and capsule manufacturing operations.

 

In December 2022, MDC Warehousing and Distribution, Inc. entered into a lease agreement for 12,500 square feet of warehouse space in Elizabeth, New Jersey.  This lease provides for minimum annual rent payments starting at $134 in year one, with a gradual increase to $150 by year 5.  The lease expiration date is November 30, 2027.

 

On October 22, 2014, AgroLabs entered into a lease agreement for an office suite located in Miami, Florida. On December 18, 2022, AgroLabs renewed this lease with minimum annual payments of approximately $10. This renewed lease will expire in February 2024.

 

Item 3. Legal Proceedings

 

From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

 

Item 4. Mine Safety Disclosure

 

Not Applicable

 

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Market Information

 

Effective January 22, 2021, our common stock was upgraded to the OTCQX® Best Market of the OTC Markets Group, Inc. and commenced quotation under the symbol “INBP” on the OTCQX® Best Market.  Prior to January 22, 2021, our common stock was quoted on the OTCQB under the symbol INBP.

 

Set forth below are the high and low bid quotation of the Company’s common stock as quoted on the OTCQX® Best Market, for each of the fiscal quarters in the fiscal years ended June 30, 2023 and 2022. Such quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.

 

 

COMMON STOCK		HIGH				LOW
FISCAL YEAR ENDED June 30, 2022
First Quarter		$	1.150			$	0.900
Second Quarter		$	1.090			$	0.880
Third Quarter		$	1.020			$	0.750
Fourth Quarter		$	0.800			$	0.410
FISCAL YEAR ENDED June 30, 2023
First Quarter		$	0.5500			$	0.4300
Second Quarter		$	0.4400			$	0.3502
Third Quarter		$	0.3800			$	0.2605
Fourth Quarter		$	0.3720			$	0.2200
July 1, 2023 to September 8, 2023		$	0.3325			$	0.2600

 

 

Holders

 

As of September 15, 2023, there were approximately 71 holders of record of the Company’s common stock. This number does not include beneficial owners holding shares through nominee names.

 

Dividends

 

We have not declared or paid a dividend with respect to our common stock during the fiscal years ended June 30, 2023 and 2022, nor do we anticipate paying dividends in the foreseeable future.

 

 

Equity Compensation Plans

 

The following table provides information, as of June 30, 2023, about the Company's equity compensation plans:

 

		Equity Compensation Plan Information
		Number of securities to be issued upon exercise of outstanding options, warrants and rights				Weighted-average exercise price of outstanding options, warrants and rights				Number of securities remaining available for future issuance under equity compensation plans (excluding securities
		(a)				(b)				reflected in column (a))
Equity compensation plans approved by security holders			4,376,284			$	0.35				6,874,718
Equity compensation plans not approved by security holders			-				-				-
Totals			4,376,284			$	0.35				6,874,718

 

Recent Sales of Unregistered Securities

 

None.

 

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

 

During the quarter ended June 30, 2023, neither we nor any “affiliated purchaser,” as that term is defined in Rule 10b-18(a)(3) under the Exchange Act, purchased any of our common stock or other securities.

 

Item 6.  [Reserved]

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations (dollars in thousands).

 

Certain statements set forth under this caption constitute “forward-looking statements.” See “Cautionary Statement Regarding Forward-Looking Statements” on page 3 of this Annual Report on Form 10-K for additional factors relating to such statements.

 

The Company is engaged primarily in the business of manufacturing, distributing, marketing and sale of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily throughout the United States and Luxembourg.

 

Our financial results are substantially dependent on net sales. Net sales are partly dependent on the mix of contract manufactured products and other nutraceutical sales, which are difficult to forecast. Factors that could cause demand to be different from our expectations include: customer acceptance of our pricing and our competitors’ pricing; changes in customer order patterns; changes in the level of customer inventory; and changes in business and economic conditions, including conditions in the credit market that could affect consumer confidence and result in lower than expected demand for our manufactured products and to a lesser extent, our other nutraceutical business products and services.

 

We believe that we have established and developed business relationships, facilities, personnel, product offerings, and competitive and financial resources in place for business success; however, future revenue, costs, gross margins, and profits are all influenced by a number of factors, including those discussed above, all of which are inherently difficult to forecast. Except as otherwise noted, all dollar amounts below are “in thousands”.

 

 

 

 

In the fiscal year ended June 30, 2023, our net sales from operations decreased by $5,574 to approximately $50,672 from approximately $56,246 in the fiscal year ended June 30, 2022.  Our net sales in the Contract Manufacturing Segment decreased by $5,814 and net sales in our Other Nutraceuticals Segment increased by $240.  Net sales decreased in our Contract Manufacturing Segment primarily due to decreased sales volumes to Life Extension and Herbalife, our two significant customers, in the amount of $2,571 and $2,708, respectively.  In the fiscal year ended June 30, 2023, our gross profit decreased by approximately $2,491 to $4,061 from approximately $6,552 for the fiscal year ended June 30, 2022.  Our profit margins decreased by 3.7% in the fiscal year ended June 30, 2023, from 11.7% in the fiscal year ended June 30, 2022 to 8.0% in the fiscal year ended June 30, 2023, primarily as a result of the decreased sales volume in the fiscal year ended June 30, 2023 compared to the fiscal year ended June 30, 2022.  We had consolidated selling and administrative expenses of approximately $3,941 and $3,807 in the fiscal years ended June 30, 2023 and 2022, respectively.  The increase in the consolidated selling and administrative expenses of $134, or approximately 3.5%, was primarily from the increase professional and consulting fees of $71 and office rent of $55.  We had additional legal fees of $23, auditing fees of $20 and all other consulting of $28 in the fiscal year ended June 30, 2023 as compared to the fiscal year ended June 30, 2022.  The increase in office rent was from the allocation of office space from the Third Lease Amendment with Vitamin Realty. In the fiscal years ended June 30, 2023 and 2022, we had operating income of approximately $120 and $2,745, respectively.

 

Our revenue from our two significant customers in our Contract Manufacturing Segment is dependent on their demand within their respective distribution channels for the products we manufacture for them.  As in any competitive market, our ability to match or beat other contract manufacturers pricing for the same items may also alter our outlook and the ability to maintain or increase revenues.  We will continue to focus on our core businesses and push forward in maintaining our cost structure in line with our sales and expanding our customer base.

 

We are currently experiencing negative impacts on our margins due to inflation and tightened labor markets.  We may not be able to timely increase our selling prices to our customers resulting from price increases from our suppliers due to various economic factors, including inflation, labor and shipping costs and our own increases in shipping, labor and other operating costs.  Our results of operations may also be affected by economic conditions, including inflationary pressures, that can impact consumer disposable income levels and spending habits, thereby reducing the orders we may receive from our significant customers.

 

We continue to experience minimal supply chain disruptions relating to fuel refinery and transportation issues as it pertains to shipping.  These issues first arose as result of the COVID-19 pandemic and other geo-political events. 

 

During the first quarter of calendar 2022, the war in Ukraine affected our customer’s business operations in Ukraine and Russia, resulting in the cancelation of some future orders. The war resulted in the imposition of sanctions by the United States, the United Kingdom, and the European Union, that affect the cross-border operations of businesses operating in Russia. In addition, many multinational companies ceased or suspended their operations in Russia. Therefore, the ability to continue operations in Russia by our customers remains uncertain.

 

Critical Accounting Policies and Estimates

 

Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The most significant estimates include:

 

 

 

●    sales returns and allowances;

●    allowance for doubtful accounts;

●    inventory valuation;

●    valuation and recoverability of long-lived assets;

●    income taxes and valuation allowances on deferred income taxes; and

●    accruals for, and the probability of, the outcome of current litigation, if any.

 

On a continual basis, management reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.

 

Allowances for Doubtful Accounts and Sales Returns

 

Our management makes judgments as to its ability to collect outstanding receivables and provides allowances for the portion of receivables for which collection becomes doubtful. Provisions are made based upon a specific review of all significant outstanding amounts. We continuously monitor payments from our customers and maintain allowances for estimated losses for doubtful accounts in the period they become known.

 

If the historical data we use to calculate the allowance provided for doubtful accounts does not reflect the future ability to collect outstanding receivables, additional provisions for doubtful accounts may be needed and the future results of operations could be materially affected. In recording any additional allowances, a respective charge against income is reflected in the general and administrative expenses; and would reduce the operating results in the period in which the increase is recorded.

 

Our return policy in our contract manufacturing business is to only accept returns for defective products. If defective products are returned, our agreement with our customers is to cure the defect and re-ship the product. Based on this policy, when the product is shipped we make an estimate of any potential returns or allowances. With respect to our branded proprietary nutraceutical products, our return policy is also to accept returns for defective products and re-ship replacement items for the damaged product. In most instances, the damaged goods are a small portion of the overall order and we instruct our customer to dispose of the damaged product and we issue them a credit for the dollar amount of the damaged goods plus any cost of disposal. We also estimate and make allowances at the time of shipment.

 

Inventory Valuation

 

Inventories are stated at the lower of cost or net realizable value, which reflects management’s estimates of net realizable value. Cost is determined using the first-in, first-out method. As a result of our inventory being manufactured primarily on a purchase order basis, the quantity of both raw materials and finished goods inventory provides for minimal risk of potential overstock or obsolescence.

 

Mail and Internet order inventory is expiration date sensitive. Accordingly, we review this inventory, consider sales levels (by SKU), term to expiration date, potential for retesting to extend expiration date, and evaluate potential for obsolescence or overstock.

 

Long Lived Assets

 

We record impairment losses on long lived assets when events and circumstances indicate that such assets might be impaired and the estimated fair value of any such asset is less than its recorded amount. The Company reviews the value of its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Conditions that would necessitate an impairment assessment include material adverse changes in operations, significant adverse differences in actual results in comparison with initial valuation forecasts prepared at the time of acquisition, a decision to abandon certain acquired products, services, or marketplaces, or other significant adverse changes that would indicate the carrying amount of the recorded asset might not be recoverable. Tests for impairment or recoverability are performed at least annually and require significant management judgment and the use of estimates which the Company believes are reasonable and appropriate at the time of the impairment test. The Company also re-evaluates the periods of amortization to determine whether circumstances warrant revised estimates of current useful lives. No impairment losses were identified in the fiscal years ended June 30, 2023 or 2022.

 

 

 

 

 

Income Taxes

 

The Company records deferred tax assets and liabilities for the estimated future tax effects of temporary differences between tax bases of assets and liabilities and amounts reported in the accompanying consolidated balance sheets, as well as operating losses and tax credit carry-forwards. The Company measures deferred tax assets and liabilities using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company reduces deferred tax assets by a valuation allowance if, based on available evidence, it is more likely than not that these benefits will not be realized.

 

The Company uses a recognition threshold and measurement attribute for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities.

 

General Litigation

 

From time to time, the Company is a defendant or plaintiff in various legal actions which arise in the normal course of business. As such, the Company is required to assess the likelihood of any adverse outcomes to these matters as well as potential ranges of probable losses. A determination of the amount of the provision required for these commitments and contingencies, if any, which would be charged to earnings, is made after careful analysis of each matter. The provision may change in the future due to new developments or changes in circumstances. Changes in the provision could increase or decrease the Company’s earnings in the period the changes are made. In the opinion of management, after consultation with legal counsel, the ultimate resolution of these matters cannot be determined at this time as to the whether there could be material adverse effect on our financial condition or results of operations.

 

Revenue Recognition

 

The Company recognizes product sales revenue, the prices of which are fixed and determinable, when title and risk of loss have transferred to the customer, when estimated provisions for product returns, rebates, charge-backs and other sales allowances are reasonably determinable, and when collectability is reasonably assured. Accruals for these items are presented in the consolidated financial statements as reductions to sales. The Company’s net sales represent gross sales invoiced to customers, less certain related charges for discounts, returns, rebates, charge-backs and other allowances. Cost of sales includes the cost of raw materials and all labor and overhead associated with the manufacturing and packaging of the products. Gross margins are affected by, among other things, changes in the relative sales mix among our products and valuation and/or charge off of slow moving, expired or obsolete inventories. To perform revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps:

 

●

identification of the promised goods or services in the contract;

●

determination of whether the promised goods or serves are performance obligations including whether they are distinct in the context of the contract;

●

measurement of the transaction price, including the constraint on variable consideration;

●

allocation of the transaction price to the performance obligations based on estimated selling prices; and

●

recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise to transfer a distinct good or service to the customer and is the unit of account in ASC 606.

 

 

 

Results of Operations (in thousands, except share and per share amounts)

 

The following table sets forth the income statement data of the Company as a percentage of net sales for the periods indicated:

 

 

		For the Fiscal Year Ended June 30,
		2023				2022
Sales, net			100.0	%			100.0	%
Costs and expenses:
Cost of sales			92.0	%			88.3	%
Selling and administrative			7.8	%			5.8	%
Total costs and expenses			99.8	%			95.1	%
Income from operations			0.2	%			4.9	%
Other income (expense), net:
Interest expense			(0.2	%)			(0.3	%)
Unrealized gain (loss) on investment in iBio, Inc.			0.1	%			(0.1	%)
Realized loss on sale of iBio, Inc. common stock			(0.1	%)			-	%
Other income (expense), net			0.1	%			0.1	%
Total other income (expense), net			(0.1	%)			(0.3	%)
Income before income taxes			0.2	%			4.6	%
Federal and state income tax (expense) benefit, net			(0.3	%)			2.2	%
Net (loss) income			(0.1	%)			6.8	%

 

Year ended June 30, 2023 Compared to the Year ended June 30, 2022

 

Sales, net.  Net sales for the fiscal year ended June 30, 2023 and 2022 were $50,672 and $56,246, respectively, a decrease of $5,574 or 9.9%. The decrease is comprised of the following:

 

 

		Fiscal Year Ended								Dollar Increase				Percentage
		June 30,								(Decrease)				Change
		2023				2022				2023 vs 2022				2023 vs 2022
		(dollars in thousands)
Contract Manufacturing:
US Customers		$	40,230			$	44,450			$	(4,220	)			(9.5	%)
International Customers			8,047				9,641				(1,594	)			(16.5	)%
Net sales, Contract Manufacturing			48,277				54,091				(5,814	)			(10.7	%)
Other Nutraceuticals:
US Customers			2,387				2,067				320				15.5	%
International Customers			8				88				(80	)			(90.9	%)
Net sales, Other Nutraceuticals			2,395				2,155				240				11.1	%
Total net sales		$	50,672			$	56,246			$	(5,574	)			(9.9	%)

 

 

 

In the fiscal years ended June 30, 2023 and 2022, a significant portion of our consolidated net sales, approximately 89% and 90%, respectively, were concentrated among two customers, Life Extension and Herbalife, customers in our Contract Manufacturing Segment.  Life Extension and Herbalife represented approximately 70% and 24% and 67% and 26%, respectively, of our Contract Manufacturing Segment’s net sales in the fiscal years ended June 30, 2023 and 2022, respectively.  Three other customers, Thermosource Tooling and Manufacturing, Hotpack Global, Inc. and ThermoFisher Scientific, (customers of our Other Nutraceutical Businesses Segment), while not significant customers of our consolidated net sales, represented 56%, 16% and 9% and 40%, 1% and 19%, respectively, of the Other Nutraceutical Businesses net sales in the fiscal years ended June 30, 2023 and 2022, respectively. The loss of any of these customers could have a significant adverse impact on our financial condition and results of operations.

 

 

The decrease in net sales of approximately $5,574 was primarily the result of decreased net sales in our Contract Manufacturing Segment by approximately $5,814 which was primarily due to decreased sales volumes to each of our major customers, Life Extension and Herbalife, in the amounts of $2,571 and $2,708, respectively, in the fiscal year ended June 30, 2023, compared to the comparable prior year.  Net sales increased by $240 in the Other Nutraceuticals Segment primarily as a result of increased sales of $849 in MDC Warehousing and Distribution, Inc., offset by decreases in Chem and IHT of $491 and $118, respectively.

 

Cost of sales.  Cost of sales decreased by $3,083 to $46,611 for the fiscal year ended June 30, 2023, as compared to $49,694 for the fiscal year ended June 30, 2022, a decrease of approximately 6.2%. Cost of sales as a percentage of sales was approximately 92% and 88% for the fiscal years ended June 30, 2023 and 2022, respectively. The decrease in the cost of goods sold amount is consistent and expected with the decrease in net sales. The increase in the cost of goods sold as a percentage of net sales and the resulting decrease in gross profit, was primarily the result of the decreased net sales and the increased costs of raw materials and freight charges that were not timely passed on to our customers.

 

Selling and Administrative Expenses.  There was an increase in selling and administrative expenses of $134 or approximately 3.5% in the fiscal year ended June 30, 2023 as compared to the fiscal year ended June 30, 2022.  As a percentage of sales, net, selling and administrative expenses were approximately 7.8% and 6.8% for the fiscal year ended June 30, 2023 and 2022, respectively.  The increase was primarily from the increase professional and consulting fees of $71 and office rent of $55.  We had additional legal fees of $23, auditing fees of $20 and all other consulting of $28 in the fiscal year ended June 30, 2023 as compared to the fiscal year ended June 30, 2022.  The increase in office rent was from the allocation of office space from the Third Lease Amendment with Vitamin Realty. All other selling and administrative expenses had a net increase of $8, no other individual expense component changed by more the $40.

 

Other income (expense), net. Other income (expense), net was approximately $(20) for the fiscal year ended June 30, 2023 compared to $(148) for the fiscal year ended June 30, 2022, and is composed of:

 

		Fiscal Year Ended
		June 30,
		2023				2022
		(dollars in thousands)
Other income (expense):
Interest expense		$	(52	)		$	(128	)
Realized loss on sale of investment			(35	)			-
Unrealized gain (loss) on investment			27				(55	)
Other income (expense), net			40				35
Total Other income (expense), net		$	(20	)		$	(148	)

 

 

Our interest expense in the fiscal year ended June 30, 2023 decreased by $76 from the fiscal year ended June 30, 2022, primarily resulting from lower average daily balances outstanding under the Senior Credit Facility with PNC in the fiscal year ended June 30, 2023.

 

In the fiscal years ended June 30, 2023, we sold we sold our remaining iBio Stock, for a loss of $35 with no such sales in the fiscal year ended June 30, 2022.  Also, in the fiscal years ended June 30, 2023 and 2022, we had an unrealized gain of approximately $27 and an unrealized loss of $55, respectively, on the remaining iBio Stock. 

 

In the fiscal years ended June 30, 2023 and 2022, we had other income of $0 and $13, respectively from providing back office and operational support for unrelated entities that sell consumer products through retail and internet-based outlets. The balance of other income (expense), net was primarily from interest income of $39 and $1 from gain on the disposition of property and equipment in the fiscal year ended June 30, 2023 compared to $22 from gains on the disposition of property and equipment in the fiscal year ended June 30, 2022.

 

 

 

 

Federal and state income tax, net.  In the fiscal years ended June 30, 2022, we released the valuation reserves for the deferred tax assets related to our federal net operating losses in the amount of $2,118. Management determined that the amount of the release was more likely than not to be realized by the Company.  In the fiscal year ended June 30, 2023 and 2022, we had current federal income taxes of $110 and $600 and deferred income tax benefits of $55 and $2,106, respectively and current state tax expense of approximately $161 and $289, respectively and deferred state tax expense of $18 in the fiscal year ended June 30, 2023 and a deferred state tax benefit in the fiscal year ended June 30, 2022.

 

We continue to maintain a reserve on a portion of our deferred tax assets as it has been determined that it is “more likely than not” that the Company’s deferred tax assets, other than federal net operating losses, may not be fully realized.

 

The decrease in the state tax expense from 2022 to 2023 was the result of decreased taxable income for the combined group.

 

Net (loss) income.  Our net (loss) income for the fiscal year ended June 30, 2023 and 2022 was approximately $(34) and $3,838, respectively.  The decrease of approximately $3,872 was primarily the result of decreased operating income of $2,625, and net decrease in the income tax (expense) benefit, net in amount $1,375.

 

Liquidity and Capital Resources

 

The following table sets forth, for the periods indicated, the Company’s net cash flows provided by or used in operating, investing and financing activities:

 

		For the fiscal year ended June 30,
		2023				2022
		(dollars in thousands)
Net cash provided by operating activities		$	1,121			$	4,091
Net cash used in investing activities		$	(111	)		$	(465	)
Net cash used in financing activities		$	(136	)		$	(3,505	)
Cash at end of year		$	1,316			$	331

 

 

At June 30, 2023 and 2022, the Company had working capital of $11,544 and $11,363, respectively. Our current liabilities decreased by approximately $435 and our current assets decreased by $254 from June 30, 2022 to June 30, 2023.  The decrease in current liabilities is primarily from the decrease of $101 in advances under revolving credit and a net decrease in accounts payable, accrued expenses and other current liabilities of $722, offset by an increase in operating lease obligations of $388.  Our current assets decrease was primarily from a decrease in inventory and accounts receivable of $794 and $377, respectively, offset by the increase in cash of $985.

 

Operating Activities

 

Net cash provided by operating activities of $1,232 in the fiscal year ended June 30, 2023 includes a net loss of approximately $34. After excluding the effects of non-cash expenses and income, depreciation and amortization, compensation expense for employee stock options, accretion of financial instruments, changes in deferred tax assets and unrealized gains on investments, the adjusted cash used in operations before the effect of the changes in working capital components was an increase of approximately $1,483. Cash in the amount of approximately $251 from our working capital assets and liabilities was used in our operating activities and was primarily the result of decreases in operating lease obligations of approximately $804 and accounts payable and accrued expenses and other liabilities of $429, offset, by increases in accounts receivable of $156 and inventories of $794.

 

 

 

Net cash provided by operating activities of $4,091 in the fiscal year ended June 30, 2022 includes net income of approximately $3,838. After excluding the effects of non-cash expenses and income, depreciation and amortization, compensation expense for employee stock options, accretion of financial instruments, changes in deferred tax assets and unrealized gains on investments, the adjusted cash used in operations before the effect of the changes in working capital components was an increase of approximately $3,526. Cash in the amount of approximately $564 from our working capital assets and liabilities was provided from our operating activities and was primarily the result of decreases in accounts receivable of approximately $927 and inventories of $640, offset, by decreases in operating lease obligations of $501 and accounts payable and accrued expenses and other liabilities of $417, and an increase in prepaid expenses and other assets of approximately $84.

 

Investing Activities

 

Cash used in investing activities was used for the purchase of machinery and equipment for approximately $116 and $486 in the fiscal years ended June 30, 2023 and 2022, respectively, offset in the fiscal year ended June 30, 2023 and 2022 by proceeds (i) received from the sale of fixed assets of $1 and $21, and (ii) from the sale of iBio, Stock of $4 and $0, respectively, a net use of cash of approximately $111 and $465, respectively.

 

Financing Activities 

 

Cash used in financing activities was approximately $136 for the fiscal year ended June 30, 2023, and was primarily from repayments of net advances under our revolving credit facility of $101 and payments under our financed lease obligation of $35.

 

Cash used in financing activities was approximately $3,505 for the fiscal year ended June 30, 2022 and consists of net payments under our revolving credit facility of $2,073 and repayments of principal under our term notes in the amount of $1,466 (See Note 5 to the consolidated financial statements included in this Annual Report on Form 10-K), offset by $34 received from the exercise of employee stock options.

 

As of June 30, 2023, we had cash of approximately $1,316, funds available under our revolving credit facility of approximately $6,269 and working capital of $11,544. We had income from operations of approximately $120 in the fiscal year ended June 30, 2023 and a net loss of approximately $34. The net loss includes a net federal tax provision of $55 that is a non-cash item due to our Federal net operating loss carryforwards and deferred tax assets offsetting the amounts owed. After taking into consideration our interim results and current projections, management believes that operations, together with the revolving credit facility and equipment financing will support our working capital requirements at least through the twelve-month period ending September 15, 2024.

 

Our current total annual commitments at June 30, 2023, for long term non-cancelable leases, of approximately $1,030 consists of obligations under operating leases for office and warehouse facilities and operating and finance lease obligations for the use of machinery and office equipment.

 

Capital Expenditures

 

The Company's capital expenditures in the fiscal years ended June 30, 2023 and 2022 were approximately $116 and $486, respectively. The Company has budgeted approximately $750 for capital expenditures for the fiscal year ending June 30, 2024. The total amount is expected to be funded from cash provided from the Company’s operations and from lease financing.

 

Off-Balance Sheet Arrangements

 

The Company has no off-balance sheet arrangements.

 

 

 

 

Impact of Inflation

 

The Company may not be able to timely increase its selling prices to its customer resulting from price increases from its suppliers due to various economic factors, including inflation, labor and shipping costs and its own increases in shipping, labor and other operating costs.  The Company’s results of operations may also be affected by economic conditions, including inflationary pressures, that can impact consumer disposable income levels and spending habits, thereby reducing the orders it may receive from the Company’s significant customers.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

 

The Company is a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and is not required to provide the information required under this item.

 

Item 8. Financial Statements and Supplementary Data

 

For a list of financial statements filed as part of this Annual Report on Form 10-K, see the index to consolidated financial statements on page 29.

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

Not Applicable

 

Item 9A. Controls and Procedures

 

Disclosure Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified by the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is accumulated and communicated to management, including the Co-Chief Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

 

Under the supervision and with the participation of management, including the Co-Chief Executive Officers and Chief Financial Officer, the Company has evaluated the effectiveness of its disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2023, and, based upon this evaluation, the Co-Chief Executive Officers and Chief Financial Officer have concluded that these controls and procedures are effective in providing reasonable assurance of compliance.

 

Management’s Annual Report On Internal Control Over Financial Reporting

 

The Company’s management is responsible for establishing and maintaining an adequate system of internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Internal control over financial reporting is a process designed by, or under the supervision of, the Company’s principal executive and financial officers and effected by the Company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

 

• Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;

 

 

 

• Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and

 

• Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

 

Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies and procedures may deteriorate.

 

The Company’s management, including the Co-Chief Executive Officers and Chief Financial Officer, has conducted an evaluation of the effectiveness of its internal control over financial reporting as of June 30, 2023 based on the criteria set forth in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013) (the “COSO Framework”).  Based on that evaluation, management concluded that our internal control over financial reporting was effective as of June 30, 2023.

 

Changes in Internal Control over Financial Reporting

 

Under the supervision and with the participation of management, including the Co-Chief Executive Officers and Chief Financial Officer, the Company has evaluated changes in internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended June 30, 2023 and have concluded that no change has materially affected, or is reasonably likely to materially affect, internal control over financial reporting.

 

Item 9B. Other Information

 

None.

 

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 

N/A

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance of the Registrant.

 

Incorporated by reference from the Company’s Proxy Statement for Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the close of the fiscal year ended June 30, 2023.

 

Item 11. Executive Compensation

 

Incorporated by reference from the Company’s Proxy Statement for Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the close of the fiscal year ended June 30, 2023.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

Incorporated by reference from the Company’s Proxy Statement for Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the close of the fiscal year ended June 30, 2023.

 

 

 

 

 

Item 13. Certain Relationships and Related Transactions and Director Independence

 

Incorporated by reference from the Company’s Proxy Statement for Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the close of the fiscal year ended June 30, 2023.

 

Item 14. Principal Accountant Fees and Services

 

Incorporated by reference from the Company’s Proxy Statement for Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the close of the fiscal year ended June 30, 2023.

 

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules

 

(a)

Exhibits and Index

 

(1)

A list of the financial statements filed as part of this Annual Report on Form 10-K is set forth in the index to consolidated financial statements on Page 29 and is incorporated herein by reference.

 

(2) An index of exhibits incorporated by reference or filed with this Annual Report on Form 10-K is provided below.

 

Number	Description
3.1	Certificate of Incorporation of Integrated BioPharma, Inc., as amended (7)
3.2	Certificate of Amendment to the Restated Certificate of Incorporation of Integrated BioPharma, Inc. (7)
3.3	By-Laws of Registrant (5)
4.1	Certificate of Designation of Series and Determination of Rights and Preferences of Series A Convertible Preferred Stock of Integrated BioPharma, Inc. dated June 25, 2003 (1)
4.2	Certificate of Designation of Series C and Determination of Rights and Preferences of Series C Convertible Preferred Stock of Integrated BioPharma, Inc. dated February 21, 2008 (6)
10.1	Lease Agreement between the Company and Vitamin Realty Associates, dated January 10, 1997 (2)
10.1.1	Second Amendment of Lease, dated as of January 5, 2012, between Vitamin Realty Associates, L.L.C. and InB:Manhattan Drug Company, Inc. (9)
10.1.2	Third Amendment of Lease, dated as of July 15, 2022, between Vitamin Realty Associates, L.L.C. and Manhattan Drug Company, Inc. (14)
10.2	Lease Agreement, dated as of January 5, 2012, between Vitamin Realty Associates, L.L.C. and AgroLabs, Inc. (9)
10.2.1	Amendment of Lease Agreement, dated as of May 19, 2014, between Vitamin Realty Associates, L.L.C. and AgroLabs, Inc. (11)
10.2.2	Termination of Lease Agreement, dated as of July 15, 2022, between Vitamin Realty Associates, L.L.C. and AgroLabs, Inc. (14)
10.3	Integrated Health Technologies, Inc. 2001 Stock Option Plan, as amended (8)
10.4	Separation and Distribution Agreement dated November 14, 2007, with our subsidiary INB:Biotechnologies (4)
10.5	Revolving Credit, Term Loan and Security Agreement, dated as of June 27, 2012, by and among Integrated BioPharma, Inc., InB:Manhattan Drug Company, Inc., Agrolabs, Inc., IHT Health Products, Inc., IHT Properties Corp. and Vitamin Factory, Inc. and PNC Bank, National Association. (10)
10.5.1	First Amendment to Revolving Credit, Term Loan and Security Agreement dated as of February 19, 2016 by and among Integrated BioPharma, Inc., InB: Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc., IHT Properties Corp. and Vitamin Factory, Inc. and PNC Bank, National Association. (12)
10.5.2	Second Amendment to Revolving Credit, Term Loan and Security Agreement dated as of May 15, 2019 by and among Integrated BioPharma, Inc., InB: Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc., IHT Properties Corp. and Vitamin Factory, Inc. and PNC Bank, National Association. (13)
10.5.3	Fourth Amendment to Revolving Credit, Term Loan and Security Agreement dated as of March 16, 2023 by and among Integrated BioPharma, Inc., Manhattan Drug Company, Inc. (successor-by-merger to InB:Manhattan Drug Company, Inc.), Agrolabs, Inc., IHT Health Products, Inc. IHT Properties, Inc. and Vitamin Factory, Inc. and PNC Bank, National Association. (15)
10.6	Term Note, dated as of June 27, 2012, by and among Integrated BioPharma, Inc., InB:Manhattan Drug Company, Inc., Agrolabs, Inc., IHT Health Products, Inc., IHT Properties Corp. and Vitamin Factory, Inc. and PNC Bank, National Association, in the original principal amount of $3,727,000. (10)
10.6.1	Amended and Restated Term Note dated as of February 19, 2016 by and among Integrated BioPharma, Inc., InB: Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc., IHT Properties Corp. and Vitamin Factory, Inc. and PNC Bank, National Association in the original principal amount of $3,422,160.00. (12)
10.6.2	Second Amended and Restated Term Note dated as of May 15, 2019 by and among Integrated BioPharma, Inc., InB: Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc., IHT Properties, Inc. and Vitamin Factory, Inc. and PNC Bank, National Association in the original principal amount of $ $3,585,175. (13)

 

 

10.7	Revolving Credit Note, dated as of June 27, 2012, by and among Integrated BioPharma, Inc., InB:Manhattan Drug Company, Inc., Agrolabs, Inc., IHT Health Products, Inc., IHT Properties Corp. and Vitamin Factory, Inc. and PNC Bank, National Association, in the original principal amount of $8,000,000. (10)
10.7.1	First Amendment to Revolving Credit, Term Loan and Security Agreement dated as of February 19, 2016 by and among Integrated BioPharma, Inc., InB: Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc., IHT Properties Corp. and Vitamin Factory, Inc. and PNC Bank, National Association. (12)
10.7.2	Second Amendment to Revolving Credit, Term Loan and Security Agreement dated as of May 15, 2019 by and among Integrated BioPharma, Inc., InB: Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc., IHT Properties Corp. and Vitamin Factory, Inc. and PNC Bank, National Association. (13)
10.8	Stock Pledge Agreement, dated as of June 27, 2012, between Integrated BioPharma, Inc. and PNC Bank, National Association. (10)
10.9	Mortgage and Security Agreement, dated as of June 27, 2012, by IHT Properties Corp. in favor of PNC Bank, National Association. (10)
10.10	Environmental Indemnity Agreement, dated as of June 27, 2012, by and among Integrated BioPharma, Inc., InB:Manhattan Drug Company, Inc., Agrolabs, Inc., IHT Health Products, Inc., IHT Properties Corp. and Vitamin Factory, Inc. and PNC Bank, National Association (10)
10.11	Lease Agreement between Elizabeth Industrial Park, LLC c/o Palin Enterprises, and MDC Warehousing and Distribution, Inc. dated November 22, 2022. (16)

14	Code of Business Ethics (3)
21	Subsidiaries of the Registrant (17)
23.1	Consent of Independent Registered Public Accounting Firm (17)
23.2	Consent of Independent Registered Public Accounting Firm (17)
31.1	Certification of Periodic Report by Chief Executive Officer Pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (17)
31.2	Certification of Periodic Report by Chief Financial Officer Pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (17)
32.1	Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (17)
32.2	Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (17)
101	The following financial information from Integrated BioPharma, Inc.’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023, formatted in XBRL (extensible Business Reporting Language): (i) Consolidated Statements of Operations for the fiscal years ended June 30, 2023 and 2022, (ii) Consolidated Balance Sheets as of June 30, 2023 and 2022, (iii) Consolidated Statements of Changes in Stockholders’ Equity for the fiscal years ended June 30, 2023 and 2022 , (iv) Consolidated Statements of Cash Flows for the fiscal years ended June 30, 2023 and 2022, and (v) the Notes to Consolidated Statements. (17)
104	Cover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101)

__________________________

 

 

(1)	Incorporated herein by reference to the Company’s Annual Report on Form 10-KSB for the fiscal year ended June 30, 2003, filed with the SEC on September 29, 2003.
(2)	Incorporated herein by reference to the Company’s Annual Report on Form 10-KSB for the fiscal year ended June 30, 1997, filed with the SEC on September 29, 1997.
(3)	Incorporated herein by reference to the Company’s Current Report on Form 8-K filed with the SEC on May 12, 2022.
(4)	Incorporated herein by reference to the Company's Current Report on Form 8-K filed with the SEC on November 19, 2007.
(5)	Incorporated herein by reference to the Company's Current Report on Form 8-K filed with the SEC on February 14, 2008.
(6)	Incorporated herein by reference to the Company's Current Report on Form 8-K filed with the SEC on February 22, 2008.
(7)	Incorporated herein by reference to the Company's Current Report on Form 8-K filed with the SEC on May 12, 2008 and to the Company’s Annual Report on Form 10-KSB for the fiscal year ended June 30, 2003 filed with the SEC on September 29, 2003.
(8)	Incorporated herein by reference to the Company's Definitive Proxy Statement on Form DEF 14A, as revised, filed with the SEC on October 28, 2009.
(9)	Incorporated herein by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 filed with the SEC on May 21, 2012.
(10)	Incorporated herein by reference to the Company's Current Report on Form 8-K filed with the SEC on June 29, 2012.
(11)	Incorporated herein by reference to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2014, filed with the SEC on September 8, 2014.
(12)	Incorporated herein by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2015 filed with the SEC on February 19, 2016.
(13)	Incorporated herein by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed with the SEC on May 15, 2019.
(14)	Incorporated herein by reference to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2022 filed with the SEC on September 13, 2022.
(15)	Incorporated herein by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 filed with the SEC on May 11, 2023.
(16)	Incorporated herein by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2022 filed with the SEC on February 10, 2023.
(17)	Filed herewith.

 

 

 

Item 16. Form 10-K Summary

 

None.

 

 

 

 

 

 

 

 

 

 

 

 

See accompanying notes to consolidated financial statements.

 

 

 

 

 

See accompanying notes to consolidated financial statements.

 

 

 

 

See accompanying notes to consolidated financial statements.

 

 

 

See accompanying notes to consolidated financial statements.

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

 

Note 1. Business                                             

 

Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States and Luxembourg. The Company was originally incorporated in the state of Delaware on August 31, 1995 under the name Chem International, Inc., on December 5, 2000, changed its name to Integrated Health Technologies, Inc. and, on January 29, 2003, changed its name to Integrated BioPharma, Inc.  The Company restated its certificate of incorporation in Delaware in June 2006.  The Company continues to do business as Chem International, Inc. with certain of its customers and certain vendors.

 

The Company’s business segments include: (a) Contract Manufacturing operated by Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers and (b) Other Nutraceutical Businesses which includes the operations of (i) AgroLabs, Inc. (“AgroLabs”), which distributed healthful nutritional products for sale through major mass market, grocery and drug and vitamin retailers, under the following brands: Peaceful Sleep, Wheatgrass and other products introduced into the market using the AgroLabs name (these are referred to as our branded products), (ii) The Vitamin Factory (the “Vitamin Factory”), which did sell private label MDC products, as well as our AgroLabs products, through the Internet, (iii) IHT Health Products, Inc. (“IHT”) a distributor of fine natural botanicals, including multi minerals produced under a license agreement, (iv) MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfillment services and (v) Chem International, Inc. (“Chem”), a distributor of certain raw materials for DSM Nutritional Products LLC.  The Vitamin Factory had no products available for sale and AgroLabs had no sales of its branded products in the fiscal years ended June 30, 2023 and 2022.

 

Note 2. Summary of Significant Accounting Policies

 

Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation.

 

Reclassifications. Certain prior year amounts have been reclassified to conform to the current year presentation.

 

Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The most significant estimates include:

 

●    sales returns and allowances;

●    allowance for doubtful accounts;

●    inventory valuation;

●    valuation and recoverability of long-lived assets;

●    income taxes and valuation allowance on deferred income taxes, and;

●    accruals for, and the probability of, the outcome of current litigation, if any.

 

On a continual basis, management reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.

 

 

- 36-

---

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

 

 

Revenue Recognition. The Company recognizes product sales revenue, the prices of which are fixed and determinable, when title and risk of loss have transferred to the customer, when estimated provisions for product returns, rebates, charge-backs and other sales allowances are reasonably determinable, and when collectability is reasonably assured. Accruals for these items are presented in the consolidated financial statements as reductions to sales. The Company’s net sales represent gross sales invoiced to customers, less certain related charges for discounts, returns, rebates, charge-backs and other allowances. Cost of sales includes the cost of raw materials and all labor and overhead associated with the manufacturing and packaging of the products. Gross margins are affected by, among other things, changes in the relative sales mix among our products and valuation and/or charge off of slow moving, expired or obsolete inventories. To perform revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps:

 

●

identification of the promised goods or services in the contract;

●

determination of whether the promised goods or serves are performance obligations including whether they are distinct in the context of the contract;

●

measurement of the transaction price, including the constraint on variable consideration;

●

allocation of the transaction price to the performance obligations based on estimated selling prices; and

●

recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise to transfer a distinct good or service to the customer and is the unit of account in ASC 606.

 

Shipping and Handling Costs. Shipping and handling costs were approximately $1,006 and $349 for the fiscal years ended June 30, 2023 and 2022, respectively, and are included in cost of sales in the accompanying Consolidated Statements of Operations.

 

Stock-Based Compensation. The Company has two stock-based compensation plans that have outstanding options issued in accordance with such plans. The Company periodically grants stock options to employees and directors in accordance with the provisions of its stock option plans, with the exercise price of the stock options being set at the closing market price of the common stock on the date of grant. Stock based compensation expense is recognized based on the estimated fair value, utilizing a Black-Scholes option pricing model, of the instrument on the date of grant over the requisite vesting period, which is generally three years.

 

Income Taxes. The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will not be realized.

 

The Company files a U.S. federal income tax return as well as returns for various states. The Company’s income taxes have not been examined by any tax authorities for the periods subject to review by such taxing authorities, except for the State of New Jersey tax filings for MDC and CII which were reviewed by the State of New Jersey for the then open tax periods of 2014 through 2017 and 2016 to 2019, respectively.  Uncertain tax positions, if any, taken on our tax returns are accounted for as liabilities for unrecognized tax benefits. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the Consolidated Statements of Operations. There were no liabilities recorded for uncertain tax positions at June 30, 2023 or 2022.

 

- 37-

---

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

 

 

Leases. We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities on our consolidated balance sheets.   The ROU assets related to Finance leases are included in property and equipment on our consolidated statement of financial condition. 

 

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

 

We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component.

 

Earnings Per Share. Basic earnings per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, subject to anti-dilution limitations using the treasury stock method.

 

Fair Value of Financial Instruments. Generally accepted accounting principles require disclosing the fair value of financial instruments to the extent practicable for financial instruments which are recognized or unrecognized in the balance sheet. The fair value of the financial instruments disclosed herein is not necessarily representative of the amount that could be realized or settled, nor does the fair value amount consider the tax consequences of realization or settlement.

 

In assessing the fair value of financial instruments, the Company uses a variety of methods and assumptions, which are based on estimates of market conditions and risks existing at the time. For certain instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, it was estimated that the carrying amount approximated fair value because of the short maturities of these instruments. All debt is based on current rates at which the Company could borrow funds with similar remaining maturities and approximates fair value.

 

Accounts Receivable and Allowance for Doubtful Accounts. In the normal course of business, the Company extends credit to customers. Accounts receivable, less the allowance for doubtful accounts, reflect the net realizable value of receivables, and approximate fair value. The Company believes there is no concentration of credit risk with any single customer whose failure or nonperformance would materially affect the Company’s results other than as discussed in Note 9(c) – Significant Risks and Uncertainties – Major Customers. On a regular basis, the Company evaluates its accounts receivables and establishes an allowance for doubtful accounts based on a combination of specific customer circumstances, credit conditions, and historical write-offs and collections. The allowance for doubtful accounts as of June 30, 2023 and 2022 was $37 and $85, respectively. Accounts receivable are charged off against the allowance after management determines that the potential for recovery is remote.

 

Inventories. Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. Allowances for obsolete and overstock inventories are estimated based on “expiration dating” of inventory and projection of sales.

 

- 38-

---

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

 

Property and Equipment. Property and equipment are recorded at cost and are depreciated using the straight line method over the following estimated useful lives:

 

Building	15 Years
Leasehold Improvements	Shorter of estimated useful life or term of lease
Machinery and Equipment	7 Years
Transportation Equipment	5 Years

                     

Impairment of Long-Lived Assets. Long-lived assets are reviewed for impairment when circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows estimated by the Company to be generated by such assets. If such assets are considered to be impaired, the impairment to be recognized is the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of by sale are recorded as held for sale at the lower of carrying value or estimated net realizable value. Tests for impairment or recoverability are performed at least annually and require significant management judgment and the use of estimates which the Company believes are reasonable and appropriate at the time of the impairment test. Future unanticipated events affecting cash flows and changes in market conditions could affect such estimates and result in the need for an impairment charge. The Company also re-evaluates the periods of amortization to determine whether circumstances warrant revised estimates of current useful lives. No impairment losses were identified or recorded in the fiscal years ended June 30, 2023 and 2022 on the Company’s long-lived assets.

 

Investment in iBio, Inc. Prior to the adoption of ASU 2016-01 on July 1, 2018, the Company accounted for its investment in iBio, Inc. (“iBio”) common stock on the cost basis as it retained approximately 6% of its interest in iBio (the “iBio Stock”) at the time of the spin-off of this subsidiary in August 2008.  The Company reviewed its investment in iBio for impairment and recorded a loss when there was deemed to be a permanent impairment of the investment.  To date, there were cumulative impairment charges of approximately $2,562. ASU 2016-01, requires equity investments to be measured at fair value and recognize changes in fair value in net income.  During the year ended June 30, 2023 and 2022, the Company recognized realized losses of $35 and $0, respectively and unrealized gain (loss) of $27 and $(55) for the fiscal years ended June 30, 2023 and 2022, respectively.  As of June 30, 2023, the Company no longer owns any iBio Stock and as of June 3, 2022, the market value of the iBio Stock was approximately $12, based on the trade price at the close of trading on June 30, 2022.  The investment in iBio is included in other current assets in the consolidated balance sheets as of June 30, 2022 at the respective market value.

 

Accounting Pronouncements Adopted

 

In June 2016, the FASB issued ASU 2016-13 “Financial Instruments-Credit Losses-Measurement of Credit Losses on Financial Instruments”. This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance applies to loans, accounts receivable, trade receivables and other financial assets measured at amortized cost, loan commitments, debt securities and beneficial interests in securitized financial assets, but the effect on the Company is projected to be limited to accounts receivable. The guidance was effective for the fiscal year beginning on July 1, 2023, including interim periods within that year. The adoption of this standard did not have a material impact on the Company’s Consolidated Financial Statements.

 

In May 2019, the FASB issued ASU 2021-05 “Financial Instruments-Credit Losses (Topic 326)” which provides transition relief for companies adopting ASU 2016-13. This guidance amends ASU 2016-13 to allow companies to elect, upon adoption of ASU 2016-13, the fair value option on financial instruments that were previously recorded at amortized cost under certain circumstances. Companies are required to make this election on and instrument by instrument basis. The guidance will be effective for the fiscal year beginning on July 1, 2023, including interim periods within that year. The adoption of this standard did  not have a material impact on the Company’s Consolidated Financial Statements.

 

- 39-

---

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

 

In October 2021, the FASB issued ASU 2021-10, Codification Improvements.  The guidance contains improvements to the Codification by ensuring that all guidance that requires or provides an option or an entity to provide information in the notes to the financial statements is codified in the Disclosure Section of the Codification.  The guidance also contains Codifications that are varied in nature and may affect the application of the guidance in cases in which the original guidance may have been unclear.  For public business entities, the amendments in the ASU are effective for annual periods beginning after December 15, 2022, and interim periods within annual periods beginning after December 15, 2023.  The adoption of ASU 2021-10 did not have a material impact on its consolidated financial statements.

 

 

Note 3. Inventories

 

Inventories are stated at the lower of cost or net realizable value using the first-in, first-out method and consist of the following:

 

		June 30,
		2023				2022
Raw materials		$	6,859			$	7,586
Work-in-process			2,148				1,759
Finished goods			1,254				1,440
Total		$	10,261			$	11,055

 

Note 4. Property and Equipment, net

 

Property and equipment consists of the following:

 

		June 30,
		2023				2022
Land and building		$	1,250			$	1,250
Leasehold improvements			1,371				1,371
Machinery and equipment			6,801				6,727
Transportation equipment			-				6
			9,422				9,354
Less:  Accumulated depreciation and amortization			(7,769	)			(7,444	)
Total		$	1,653			$	1,910

 

Depreciation and amortization expense was $351 and $336 for the fiscal years ended June 30, 2023 and 2022, respectively.  Additionally, the Company disposed of fully depreciated property of $26 and $309 in the fiscal years ended June 30, 2023 and 2022, respectively.  The Company also recognized a net gain on disposals of $0 and $2 on property, including property in the aggregate amount of $0 and $16 that were not fully depreciated and a gain on the sale of equipment of $1 and $20 in the fiscal years ended June 30, 2023 and 2022, respectively.

 

- 40-

 

---

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

Note 5. Senior Credit Facility

 

As of June 30, 2023 and 2022, the Company had the following debt outstanding:

 

		Principal Amount								Interest Rate			Maturity Date
		June 30,
		2023				2022
Revolving advances under Senior Credit Facility with PNC Bank, National Association		$	-			$	101				8.25	%	5/15/2024
Total outstanding debt		$	-			$	101

 

SENIOR CREDIT FACILITY

 

On March 16, 2023, the Company, MDC, AgroLabs, IHT, IHT Properties Corp. (“IHT Properties”) and Vitamin Factory (collectively, the “Borrowers”) amended the Revolving Credit, Term Loan and Security Agreement (the “Amended Loan Agreement”) with PNC Bank, National Association as agent and lender (“PNC”) and the other lenders party thereto entered into on June 27, 2012, as amended on February 19, 2016 and May 15, 2019.

 

The Amended Loan Agreement provides for a total of $11,585 in senior secured financing (the “Senior Credit Facility”) as follows: (i) discretionary advances (“Revolving Advances”) based on eligible accounts receivable and eligible inventory in the maximum amount of $8,000 (the “Revolving Credit Facility”), and (ii) a term loan in the amount of $3,585 (the “Term Loan”). The Senior Credit Facility is secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and common stock of iBio owned by the Company.  Revolving Advances bear interest at PNC’s Base Rate (8.25% and 4.75% as of June 30, 2023 and 2022, respectively) or the Eurodollar Rate, at Borrowers’ option, plus 2.50%. The Term Loan bore interest at PNC’s Base Rate (5.00% as of June 30, 2022) or the Eurodollar Rate at Borrowers’ option, plus 3.00%. As of September 15, 2023, the Revolving Advance interest rate is 8.50%.

 

As of March 16, 2023, the Amended Loan Agreement provides that any loans, advances and/or other extensions of credit denominated in U.S. Dollars prior to March 16, 2023 that bear interest or are permitted to bear interest, and have fees, commissions or other  amounts based on the London Interbank Offered Rate administered by the ICE Benchmark Administration (which may be referred to as the “Eurodollar Rate” ( “LIBOR”) shall thereafter bear interest based on the Term SOFR Rate plus the SOFR Adjustment . The Term SOFR Rate, for any day, shall be equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate). The SOFR Adjustment is defined as 10 basis points (0.10%).

 

Upon and after the occurrence of any event of default under the Amended Loan Agreement, and during the continuation thereof, interest shall be payable at the interest rate then applicable plus 2%. The Senior Credit Facility matures on May 15, 2024 (the “Senior Maturity Date”).

 

The principal balance of the Revolving Advances is payable on the Senior Maturity Date, subject to acceleration, based upon a material adverse event clause, as defined, subjective accelerations for borrowing base reserves, as defined or upon the occurrence of any event of default under the Amended Loan Agreement or earlier termination of the Amended Loan Agreement pursuant to the terms thereof. The Term Loan shall be repaid in eighty-four (84) consecutive monthly installments of principal, the first eighty-three (83) of which shall be in the amount of $43, commencing on the first business day of June 2019, and continuing on the first business day of each month thereafter, with a final payment of any unpaid balance of principal and interest payable on the Senior Maturity Date. The foregoing is subject to customary mandatory prepayment provisions and acceleration upon the occurrence of any event of default under the Amended Loan Agreement or earlier termination of the Amended Loan Agreement pursuant to the terms thereof.  The Company satisfied all the principal payments required under the Term Note on January 3, 2022. 

 

- 41-

---

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

 

The Revolving Advances are subject to the terms and conditions set forth in the Amended Loan Agreement and are made in aggregate amounts at any time equal to the lesser of (x) $8,000 or (y) an amount equal to the sum of: (i) up to 85%, subject to the provisions in the Amended Loan Agreement, of eligible accounts receivables (“Receivables Advance Rate”), plus (ii) up to the lesser of (A) 75%, subject to the provisions in the Amended Loan Agreement, of the value of the eligible inventory (“Inventory Advance Rate” and together with the Receivables Advance Rate, collectively, the “Advance Rates”), (B) 85% of the appraised net orderly liquidation value of eligible inventory (as evidenced by the most recent inventory appraisal reasonably satisfactory to PNC in its sole discretion exercised in good faith) and (C) the inventory sublimit in the aggregate at any one time (“Inventory Advance Rate” and together with the Receivables Advance Rate, collectively, the “Advance Rates”), minus (iii) the aggregate Maximum Undrawn Amount, as defined in the Amended Loan Agreement, of all outstanding letters of credit, minus (iv) such reserves as PNC may reasonably deem proper and necessary from time to time.

 

The Amended Loan Agreement contains customary mandatory prepayment provisions, including, without limitation the requirement to use any sales proceeds from the sale of iBio Stock to repay the Term Loan and to prepay the outstanding amount of the Term Note in an amount equal to twenty-five percent (25%) of Excess Cash Flow, as defined in the Amended Load Agreement, for each fiscal year commencing with the fiscal year ended June 30, 2016, payable upon delivery of the financial statements to PNC referred to in and required by the Amended Loan Agreement for such fiscal year but in any event not later than one hundred twenty (120) days after the end of each such fiscal year, which amount shall be applied ratably to the outstanding principal installments of the Term Loan in the inverse order of the maturities thereof. The Amended Loan Agreement also contains customary representations and warranties, covenants and events of default, including, without limitation, (i) a fixed charge coverage ratio maintenance requirement and (ii) an event of default tied to any change of control as defined in the Amended Loan Agreement.  As of June 30, 2023, the Company was in compliance with the fixed charge coverage ratio maintenance requirement, with the required annual payments of 25% of the Excess Cash Flow for each fiscal year commencing with the fiscal year ended June 30, 2016 and used the proceeds of $96 from the sale of iBio Stock in the fiscal year ended June 30, 2021, to repay the Term Loan.  Additionally, with the required annual payment of 25% of Excess Cash Flow for the fiscal year ended June 30, 2021, together with the required monthly installments of $43, the Company satisfied all the remaining principal payments required under the Term Note on January 3, 2022.

 

In connection with the Senior Credit Facility, the following loan documents were executed: (i) a Stock Pledge Agreement with PNC, pursuant to which the Company pledged to PNC the iBio Stock; (ii) a Mortgage and Security Agreement with PNC with IHT Properties; and (iii) an Environmental Indemnity Agreement with PNC.

 

 

 

- 42-

---

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

 

Note 6. Interest Expense

 

The components of interest expense for the fiscal years ended June 30, 2023 and 2022 are presented below:

 

		For the Fiscal Year Ended June 30,
		2023				2022
Interest on Senior Debt		$	40			$	103
Amortization of prepaid financing costs			12				21
Other interest expense			-				4
Interest Expense		$	52			$	128

 

The weighted average interest rate paid was 5.67% and 3.33% in the fiscal years ended June 30, 2023 and 2022, respectively. As of June 30, 2023 and 2022, the Company had accrued unpaid interest of approximately $0 and $3, respectively.

 

Note 7. Income Taxes

 

The components of the provision for income taxes consists of the following:

 

 

		For the fiscal year
		ended June 30,
		2023				2022
Current - Federal tax expense		$	(110	)		$	(600	)
Current - State tax expense			(61	)			(289	)
Deferred - Federal benefit			55				2,106
Deferred - State tax (expense) benefit			(18	)			24
Income tax (expense) benefit, net		$	(134	)		$	1,241

 

A reconciliation of the statutory tax rate to the effective tax rate is as follows:

 

 

		For the fiscal year
		ended June 30,
		2023				2022
Statutory federal income tax rate			(21.0	)%			(21.0	)%
State income tax rate			(55.1	)%			(11.5	)%
Stock compensation			(166.0	)%			(4.6	)%
Change in valuation allowance			201.2	%			85.6	%
Other temporary differences			(62.1	)%			(0.6	)%
Loss on sale of iBio Stock			(18.4	)%			-
Non-deductible expenses			(12.6	)%			(0.1	)%
Effective income tax rate			(134	)%			47.8	%

 

 

- 43-

---

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

 

Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial accounting purposes and the amounts used for income tax reporting. Significant components of the Company’s net deferred tax assets are as follows:

 

		June 30,
		2023				2022
Deferred Tax Assets
Net operating loss		$	5,105			$	5,166
Capital loss carryover			678				485
Depreciation			(139	)			(157	)
Inventory			180				149
Other			337				296
Valuation allowance			(1,435	)			(1,141	)
Total deferred tax asset, net		$	4,726			$	4,798

 

The Company has net operating losses (“NOL”) of approximately $21,700 for federal purposes which expire beginning in 2028, which were federal NOLs generated prior to 2018.  NOLs generated post 2018 have an indefinite life, subject to 80% of taxable income, there were no NOLs generated post 2018.  State NOL’s of approximately $3,997 expire beginning in 2031 through 2039. The Company also has capital loss carryforwards of $2,343 of which $271, $1,152 and $920 will expire in 2025,   2026 and 2028, respectively. The Company files a consolidated U.S. federal income tax return; however, the various state tax returns were filed on a stand-alone basis for the Company and its subsidiaries until the fiscal year ended June 30, 2021, which state income tax return are now filed on a combined basis. MDC has fully utilized its state NOL’s resulting in taxable income on a state level basis for the combined group. 

 

Realization of the NOL carryforwards and other deferred tax temporary differences is contingent on future taxable earnings. The Company’s deferred tax asset was reviewed for expected utilization using a “more likely than not” approach by assessing the available positive and negative evidence surrounding its recoverability. Accordingly, a valuation allowance has been recorded against the Company’s deferred tax asset, as it was determined based upon past taxable losses and inconsistent taxable income in the past few years, that it was “more likely than not” that the Company’s deferred tax assets would not be realized. As of June 30, 2022, management determined that certain of the Company’s deferred tax assets were “more likely than not” to be realizable and the Company recognized deferred tax benefits related to the release of the valuation allowance on those assets of approximately $1,795.

 

The Company will continue to assess and evaluate strategies that will enable the deferred tax asset, or portion thereof, to be utilized, and will reduce the valuation allowance appropriately at such time when it is determined that the “more likely than not” criteria is satisfied.

 

There were no significant uncertain tax positions taken, or expected to be taken, in a tax return that would be determined to be an unrecognized tax benefit taken or expected to be taken in a tax return that should have been recorded on the Company’s consolidated financial statements for the year ended June 30, 2023.  Additionally, there were no interest or penalties outstanding as of or for each of the fiscal years ended June 30, 2023 and 2022.

 

The latest three years of Federal and four years of state tax returns filed for the fiscal years ended through June 30, 2023 are currently open except for the State of New Jersey tax filings for CII which have been reviewed for the tax period of 2019. The tax returns for the year ended June 30, 2023 will be filed by March 15, 2024.

 

 

- 43-

---

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

 

Note 8. Profit-Sharing Plan

 

The Company maintains a profit-sharing plan, which qualifies under Section 401(k) of the Internal Revenue Code, covering all nonunion employees meeting age and service requirements. Contributions are determined by matching a percentage of employee contributions. For the fiscal years ended June 30, 2023 and 2022, the Company contributed approximately $81 and $86, respectively, into the plan for the benefit of the eligible employees participating in the plan.

 

Note 9. Significant Risks and Uncertainties

 

(a) Concentrations of Credit Risk-Cash. The Company maintains balances at several financial institutions. Deposits at each institution are insured by the Federal Deposit Insurance Corporation up to $250. As of June 30, 2023, the Company had $1,949 in uninsured deposits at these financial institutions.

 

(b) Concentrations of Credit Risk-Receivables. The Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk of its customers, establishes an allowance for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowances is limited. The Company does not require collateral in relation to its trade accounts receivable credit risk.

 

(c) Major Customers.  In the fiscal years ended June 30, 2023 and 2022, approximately 89% and 90% of consolidated net sales, respectively, were derived from two customers. These two customers are in the Company’s Contract Manufacturing Segment and represent approximately 70% and 24% and 67% and 26%, respectively, of this segment’s net sales in the fiscal years ended June 30, 2023 and 2022, respectively.  Accounts receivable from these two major customers represented approximately 84% and 70% of total net accounts receivable as of June 30, 2023 and 2022, respectively.  Three other customers in the Other Nutraceutical Segment, while not significant customers of the Company’s consolidated net sales, represented approximately 56%, 16% and 9% and 40%, 1% and 19%, respectively, of net sales of the Other Nutraceutical Segment in the fiscal years ended June 30, 2023 and 2022, respectively.  The loss of any of these customers could have an adverse effect on the Company’s operations. Major customers are those customers who account for more than 10% of net sales.

 

(d) Business Risks. The Company insures its business and assets against insurable risks, to the extent that it deems appropriate, based upon an analysis of the relative risks and costs. The Company believes that the risk of loss from non-insurable events would not have a material adverse effect on the Company’s operations as a whole.

 

The raw materials used by the Company are primarily commodities and agricultural-based products. Raw materials used by the Company in the manufacture of its nutraceutical products are purchased from independent suppliers. Raw materials are available from numerous sources and the Company believes that it will continue to obtain adequate supplies.

 

As of June 30, 2023, approximately 74% the Company’s employees are covered by a union contract and are employed in its New Jersey facilities. The contract was renewed effective September 1, 2022 and will expire on August 31, 2026.

 

While the Company hasn’t, to date, seen a significant negative impact in its margins resulting from the coronavirus outbreak, it is experiencing a negative impact on its margins due to inflation and tightened labor markets.  The Company may not be able to timely increase its selling prices to its customer resulting from price increases from its suppliers due to various economic factors, including inflation, labor and shipping costs and its own increases in shipping, labor and other operating costs. The Company’s results of operations may also be affected by economic conditions, including inflationary pressures, that can impact consumer disposable income levels and spending habits, thereby reducing the orders it may receive from the Company’s significant customers.

 

- 45-

---

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

 

The Company continues to experience minimal supply chain disruptions relating to fuel refinery and transportation issues as it pertains to shipping.  These issues first arose as result of the COVID-19 pandemic and other geo-political events. The significant outbreak of this contagious disease in the human population has resulted in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could affect demand for the Company’s products and impact the Company’s operating results.

 

During the first quarter of calendar 2022, the war in Ukraine affected the Company’s customer’s business operations in Ukraine and Russia, resulting in the cancelation of some future orders. The war resulted in the imposition of sanctions by the United States, the United Kingdom, and the European Union, that affect the cross-border operations of businesses operating in Russia. In addition, many multinational companies ceased or suspended their operations in Russia. Therefore, the ability to continue operations in Russia by the Company’s customers is uncertain.  Also, there may be a shortage of Sunflower Oil products in the near future and this may cause delays in production of certain raw materials and may require reformulation of products.

 

Note 10. Commitments and Contingencies

 

(a) Leases. The Company has operating and finance leases for its corporate and sales offices, warehousing and packaging facilities and certain machinery and equipment, including office equipment. The Company’s leases have remaining terms of less than 1 year to less than 7 years.

 

The components of lease expense for the fiscal year ended June 30, 2023 and 2022 were as follows:

 

 

		2023												2022
		Related Party - Vitamin Realty				Other Leases				Totals				Related Party - Vitamin Realty				Other Leases				Totals
Operating Lease Costs		$	842			$	88			$	650			$	566			$	84			$	650
Finance Operating Lease Costs:
Amortization of right-of use assets		$	-			$	12			$	12			$	-			$	3			$	3
Total Finance Lease Costs		$	-			$	12			$	12			$	-			$	3			$	3

 

Rent and lease amortization costs are included in cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations.

 

Operating Lease Liabilities

 

Related Party Operating Lease Liabilities.  Warehouse and office facilities are leased from Vitamin Realty Associates, LLC (“Vitamin Realty”), which is 100% owned by the estate of the Company’s former chairman, and a major stockholder and certain of his family members, who are the Co-Chief Executive Officers and directors of the Company.  On January 5, 2012, MDC entered into a second amendment of lease (the “Second Lease Amendment”) with Vitamin Realty for its office and warehouse space in New Jersey increasing its rentable square footage from an aggregate of 74,898 square feet to 76,161 square feet and extending the expiration date to January 31, 2026.  This Second Lease Amendment provided for minimum annual rental payments of $533, plus increases in real estate taxes and building operating expenses.  On July 15, 2022, MDC entered into a third amendment of the lease (the “Third Lease Amendment”) with Vitamin Realty, increasing its rentable square footage to 116,175.  This Third Lease Amendment provided for minimum annual rental payments of $842, plus increases in real estate taxes and the building operating expenses allocation percentage and is effective as of July 1, 2022.

 

 

 

- 44-

---

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

 

On May 19, 2014, AgroLabs entered into an amendment to the lease agreement entered into on January 5, 2012, with Vitamin Realty for an additional 2,700 square feet of warehouse space in New Jersey, the term of which was to expire on January 31, 2020 to extend the expiration date to June 1, 2024. This additional lease provided for minimum lease payments of $27 with annual increases plus the proportionate share of operating expenses.  The AgroLabs Lease was mutually terminated on July 15, 2022 with an effective date of July 1, 2022.

 

Rent expense, lease amortization costs and imputed interest costs on these related party leases were $1,269 and $896 for the fiscal years ended June 30, 2023 and 2022, respectively, and are included in cost of sales and selling and administrative expenses in the accompanying Consolidated Statements of Operations. As of June 30, 2023 and 2022, the Company had outstanding current obligations to Vitamin Realty of $0 and $72, respectively, included in accounts payable in the accompanying Consolidated Balance Sheets.  Additionally, as of June 30, 2023 and 2022, the Company has operating lease obligations of $2,061 and $1,841, respectively, with Vitamin Realty as noted in the accompany Consolidated Balance Sheet.

 

Other Operating Lease Liabilities. The Company has entered into certain non-cancelable operating lease agreements expiring up through May 2023, related to machinery and equipment and office equipment. 

 

As of June 30, 2023, the Company’s ROU assets, lease obligations and remaining cash commitment on these leases is as follows:

 

		Right-of-use Assets				Current Portion Operating Lease Obligations				Operating Lease Obligations				Remaining Cash Commitment
Vitamin Realty Leases		$	2,061			$	772			$	1,289			$	1,972
Warehouse Lease			541				108				433				631
Office equipment leases			21				8				13				23
		$	2,623			$	888			$	1,735			$	2,830

 

As of June 30, 2022, the Company’s ROU assets, lease obligations and remaining cash commitment on these leases is as follows:

 

		Right-of-use Assets				Current Portion Operating Lease Obligations				Operating Lease Obligations				Remaining Cash Commitment
Vitamin Realty Leases		$	1,839			$	503			$	1,338			$	1,972
Office equipment leases			28				7				21				32
		$	1,867			$	510			$	1,359			$	2,004

 

As of June 30, 2023 and 2022, the Company’s weighted average discount rate is 4.41% and 3.87%, for the fiscal years then ended, respectively, and the remaining term on lease liabilities is approximately 2.9 years and 3.5 years, respectively.

 

 

- 45-

---

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

 

Financed Lease Obligation. 

 

On June 15, 2022, the Company entered into a financed lease obligation with LEAF Capital Funding, LLC in the amount of $85, which lease is secured by certain machinery and equipment and matures on August 15, 2024.  The lease payment in the amount of approximately $4 is payable monthly, beginning September 15, 2023 and has a stated interest rate of 0.0%.

 

As of each June, 2023 and 2022, the Company’s weighted average discount rate for the outstanding finance lease obligation is 0% and the remaining term on finance lease obligation is approximately 1.2 years and 2.2 years, respectively.  The ROU asset related to the finance lease obligation is included in Property and equipment, net in the accompanying Consolidated Balance Sheet.

 

Supplemental cash flows information related to leases for the fiscal year ended June 30, 2023 is as follows:

 

 

		Related Party - Vitamin Realty				Other Leases				Totals
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases		$	842			$	147			$	989
Operating cash flows from finance lease obligations			-				-				-
Financing cash flows from finance lease obligations			-				35				35

 

 

Supplemental cash flows information related to leases for the fiscal year ended June 30, 2022 is as follows:

 

 

		Related Party - Vitamin Realty				Other Leases				Totals
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases		$	566			$	84			$	650
Operating cash flows from finance lease obligations			-				-				-
Financing cash flows from finance lease obligations			-				-				-

 

 

In the fiscal year ended June 30, 2023, in addition to the Third Amendment with Vitamin Realty the Company renewed, for one year, an operating lease for office space with an annual commitment of $10 and entered into a five year lease for additional warehouse space of 12,500 square feet with an annual commitment of $134 in the first year increasing to $150 in the fifth year of the lease (the “Warehouse Lease”).  The Warehouse Lease includes additional rent of not less than $1 per month for the Company’s pro rata portion of the lessor’s operating expenses and commenced on December 1, 2022.  Additionally, on August 4, 2023, the Company entered into a four year operating lease for transportation equipment with an annual commitment of $21.

 

 

- 46-

---

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

 

Maturities of operating lease liabilities as of June 30, 2023 were as follows:

 

 

Year ending June 30,		Operating Lease Commitment				Related Party Operating Lease Commitment				Finance Lease Obligation				Total
2024		$	146			$	842			$	42			$	1,030
2025			149				842				7				998
2026			148				492				-				640
2027			148				-				-				148
2028			63				-				-				63
Total minimum lease payments			654				2,176				49				2,879
Imputed interest			(92	)			(115	)			-				(207	)
Total		$	562			$	2,061			$	49			$	2,672

 

 

(b) Legal Proceedings.

 

The Company is subject, from time to time, to claims by third parties under various legal theories. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.

 

Note 11. Related Party Transactions

 

See Note 10(a) - Leases for related party lease transactions.

 

Note 12. Equity Transactions and Stock-Based Compensation

 

Stock Option Plans. The Company has adopted a stock option plan for the granting of options or restricted shares to employees, officers, directors and consultants of the Company that originally provided for the issuance of up to 7,000,000 shares of common stock, at the discretion of the Board of Directors. Subsequent to the adoption, the Board of Directors and stockholders approved additional common stock shares aggregating 6,000,000 to be available for grant, for a total of 13,000,000 shares of common stock reserved for issuance under the Company’s 2001 Stock Option Plan, as amended (the “Plan”). The Company also has a 1997 Stock Option Plan with 5,000,000 shares of common stock reserved for issuance. Stock option grants may not be priced less than the fair market value of the Company’s common stock at the date of grant. Options granted are generally for ten-year periods, except that incentive stock options granted to a 10% stockholder (as defined) are limited to five-year terms. As of June 30, 2023, the Company has 6,823,569 shares of common stock remaining under the Plans.

 

In the fiscal year ended June 30, 2023, the Board of Directors authorized the issuance of up to 538,500 stock options to Company officers and employees. The Company issued 527,000 stock options with an exercise price ranging from $0.41 to $0.45, vesting over three years, with expiration terms of either five or ten years from the date of grant.  For the fiscal years ended June 30, 2023 and 2022, the Company incurred stock-based compensation expense of $320 and $369, respectively.  The Company expects to record additional stock-based compensation of $480 over the remaining estimated vesting period of approximately two and half years. 

 

In July 2023, the Board of Directors authorized the issuance of 200,000 stock options to the non-executive directors of (50,000 each) with an exercise price of $0.33, vesting over one year, 25% at the end of each quarter ending September 30, 2023, December 21, 2023, March 31, 2024 and June 30, 2024.

 

 

- 47-

---

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

 

 

 

The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during the year ended June 30, 2023:

 

Risk Free Interest Rate			3.85% to 3.00	%
Volatility			103.3% to 116.9	%
Term			4.5 to 7.5 years
Dividend Rate			0.00	%
Closing Price of Common Stock		$	0.41

 

The Company calculates expected volatility for a stock-based grant based on historic daily stock price observations of its common stock during the period immediately preceding the grant that is equal in length to the expected term of the grant. The expected term of the options is estimated based on the Company’s historical exercise rate and forfeiture rates are estimated based on employment termination experience. The risk free interest rate is based on U.S. Treasury yields for securities in effect at the time of grants with terms approximating the term of the grants. The assumptions used in the Black-Scholes option valuation model are highly subjective, and can materially affect the resulting valuations.

 

In the fiscal year ended June 30, 2022, the Board of Directors authorized the issuance of 764,700 stock options to Company officers, employees and directors with an exercise price of $0.51, $0.95 or $1.045, vesting over one or three years, with terms of either five or ten years.

 

In the fiscal years ended June 30, 2023 and 2022, stock options in the aggregate amount of 4,376,284 and 537,600, were not included in the computation of weighted average diluted common shares outstanding as the effect of doing so would have been anti-dilutive.

 

The intrinsic value of options outstanding and exercisable at June 30, 2023 and 2022 was $461 and $1,002, respectively.

 

A summary of the Company’s stock option activity, and related information for the years ended June 30, follows:

 

						Weighted
						Average
						Exercise
		Options				Price
Outstanding as of July 1, 2021			3,916,666			$	0.26
Granted			764,700				0.85
Exercised			(146,333	)			0.23
Terminated			(44,700	)			0.53
Expired			(46,400	)			0.47
Outstanding as of June 30, 2022			4,443,933				0.36
Granted			527,000				0.42
Exercised			-				-
Terminated			-				-
Expired			(594,649	)			0.46
Outstanding as of June 30, 2023			4,376,284			$	0.35
Exercisable at June 30, 2022			3,524,500			$	0.26
Exercisable at June 30, 2023			3,626,551			$	0.30

 

 

- 48-

---

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

 

The following table summarizes the range of exercise prices and weighted-average exercise prices for stock options outstanding and exercisable as of June 30, 2023 under the Company’s stock option plans:

 

																Weighted
									Weighted			Weighted Average				Average
									Average			Remaining				Exercise
Range of Exercise Price						Outstanding			Exercise Price			Contractual Life (years)	Exercisable			Price
$	0.09	-	$	0.10			1,221,000		$	0.09		1.9		1,296,000		$	0.09
$	0.21	-	$	0.21			1,194,000			0.21		5.9		1,209,000			0.21
$	0.23	-	$	0.25			250,000			0.23		3.4		250,000			0.23
$	0.41	-	$	0.41			426,500			0.41		9.4		-			0.00
$	0.51	-	$	0.51			200,000			0.51		9.0		200,000			0.51
$	0.65	-	$	0.65			570,667			0.65		7.4		431,000			0.65
$	0.72	-	$	0.72			66,667			0.72		0.7		66,667			0.72
$	0.95	-	$	0.95			425,783			0.95		8.4		242,217			0.95
$	1.05	-	$	1.05			21,667			1.05		0.7		21,667			1.05
$	0.09	-	$	1.05			4,376,284		$	0.35		7.0		3,626,551		$	0.30

 

Note 13. Segment Information

 

The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments.

 

The Company has divided its operations into two reportable segments; Contract Manufacturing and Other Nutraceutical Businesses. The international sales, concentrated primarily in Europe, for the fiscal years ended June 30, 2023 and 2022 were $8,055 and $9,729, respectively.

 

Financial information relating to the fiscal years ended June 30, 2023 and 2022 operations by business segment are as follows:

 

 

			Sales, Net												Segment
			U.S.				International								Gross								Capital				Total
			Customers				Customers				Total				Profit				Depreciation				Expenditures				Assets
Contract Manufacturing	2023		$	40,230			$	8,047			$	48,277			$	3,630			$	348			$	109			$	19,507
	2022			44,450				9,641				54,091				5,917				332				486				19,061
Other Nutraceutical Businesses	2023			2,387				8				2,395				431				3				7				5,924
	2022			2,067				88				2,155				635				4				-				6,189
Total Company	2023			42,617				8,055				50,672				4,061				351				116				25,431
	2022			46,517				9,729				56,246				6,552				336				486				25,250

 

 

- 51-

---

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

	INTEGRATED BIOPHARMA, INC.
Date:  September 15, 2023	By: /s/ Christina Kay
	Christina Kay
	Co-Chief Executive Officer
Date:  September 15, 2023	By: /s/ Dina L. Masi
	Dina L. Masi
	Chief Financial Officer

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons in the capacities and on the dates indicated.

 

 

Name		Title		Date
/s/ Christina Kay		Co-Chief Executive Officer and Director		September 15, 2023
Christina Kay		(Principal Executive Officer)
/s/ Riva Sheppard		Co-Chief Executive Officer and Director		September 15, 2023
Riva Sheppard		(Principal Executive Officer)
/s/ Dina L. Masi		Chief Financial Officer		September 15, 2023
Dina L. Masi		(Principal Financial Officer and
		Principal Accounting Officer)
/s/ Robert Canarick		Director		September 15, 2023
Robert Canarick
/s/ Damon DeSantis		Director		September 15, 2023
Damon DeSantis
/s/ William H. Milmoe		Director		September 15, 2023
William H. Milmoe
/s/ Eric Friedman		Director		September 15, 2023
Eric Friedman

 

EXHIBIT 21

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

SUBSIDIARIES OF THE REGISTRANT

 

Subsidiary Name	State of Incorporation
Manhattan Drug Company, Inc.	New Jersey
AgroLabs, Inc.	New Jersey
IHT Health Products, Inc.	Delaware
Vitamin Factory, Inc.	Delaware
IHT Properties, Inc.	Delaware
MDC Warehousing and Distribution, Inc. (f/k/a The Organic Beverage Company)	New Jersey
InB:Paxis Pharmaceuticals, Inc. (f/k/a Paxis Pharmaceuticals, Inc.) - inactive	Delaware

 

Exhibit 23.1

 

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT

 

We consent to the incorporation by reference in the Registration Statements of Integrated BioPharma, Inc. on Form S-8 (File Nos. 333-229069, 333-37509, 333-87456 and 333-87458) and Form S-3 (File Nos. 333-144155 and 333-149855) of our report dated September 15, 2023, with respect to our audits of the consolidated financial statements of Integrated BioPharma, Inc. as of June 30, 2023 and for the year ended June 30, 2023, which report is included in this Annual Report on Form 10-K of Integrated BioPharma, Inc. for the year ended June 30, 2023.

 

/s/ Marcum LLP

 

Marcum LLP

 

East Hanover, NJ

 

September 15, 2023

 

EXHIBIT 23.2

CONSENT OF INDEPENDENT REGISTERED ACCOUNTANTING FIRM

 

 

We hereby consent to the incorporation by reference in the Registration Statements of Integrated BioPharma, Inc. on Form S-8 (File Nos. 333-229069, 333-37509, 333-87456 and 333-87458) and Form S-3 (File Nos. 333-144155 and 333-149855) of our report dated September 13, 2022, with respect to our audit of the consolidated financial statements as of June 30, 2022, and for the year ended June 30, 2022, which was included in the Company’s Annual Report on Form 10-K filed on September 15, 2023. We were dismissed as auditors on September 21, 2022 and, accordingly, we have not performed any audit or review procedures with respect to any financial statements incorporated by reference for the periods after the date of our dismissal.

 

 

/s/ Friedman LLP

East Hanover, NJ

September 15, 2023

 

 

Exhibit 31.1

 

CERTIFICATION

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

We, Christina Kay and Riva Sheppard, Co-Chief Executive Officers, certify that:

 

1.

We have reviewed this annual report on Form 10-K of Integrated BioPharma, Inc.;

 

2.

Based on our knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on our knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant's other certifying officer(s) and we are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.

The registrant's other certifying officer(s) and we have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: September 15, 2023	By: /s/ Christina Kay
	Name: Christina Kay
	Title: Co-Chief Executive Officer
Date: September 15, 2023	By: /s/ Riva Sheppard
	Name: Riva Sheppard
	Title: Co-Chief Executive Officer

 

Exhibit 31.2

 

CERTIFICATION

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Dina L. Masi, Senior Vice President & Chief Financial Officer, certify that:

 

1.

I have reviewed this annual report on Form 10-K of Integrated BioPharma, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

 

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:

 

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: September 15, 2023	By: /s/ Dina L. Masi
	Name: Dina L. Masi
	Title: Senior Vice President & Chief Financial Officer

 

Exhibit 32.1

 

 

CERTIFICATION

 

As adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

In connection with the Annual Report on Form 10-K for the fiscal year ended June 30, 2023 of Integrated BioPharma, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Christina Kay and Riva Sheppard, Co-Chief Executive Officers of Integrated BioPharma, Inc. (the "Company"), certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to their knowledge:

 

(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

 

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

  

 

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended.

 

A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

Date: September 15, 2023	By: /s/ Christina Kay
	Christina Kay
	Co-Chief Executive Officer
Date: September 15, 2023	By: /s/ Riva Sheppard
	Riva Sheppard
	Co-Chief Executive Officer

 

Exhibit 32.2

 

 

CERTIFICATION OF PERIODIC REPORT

 

As adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

In connection with the Annual Report on Form 10-K for the fiscal year ended June 30, 2023 of Integrated BioPharma, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Dina L. Masi, the Senior Vice President and Chief Financial Officer of Integrated BioPharma, Inc. (the "Company"), certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to her knowledge:

 

(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

 

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

  

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended.

 

A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

Date: Date: September 15, 2023	By: /s/ Dina L. Masi
	Dina L. Masi
	Senior Vice President and Chief Financial Officer

 

v3.23.2

Document And Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2023	Sep. 15, 2023	Dec. 31, 2022
Document Information [Line Items]
Entity Central Index Key	0001016504
Entity Registrant Name	INTEGRATED BIOPHARMA INC
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-31668
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	22-2407475
Entity Address, Address Line One	225 Long Ave.
Entity Address, City or Town	Hillside
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07205
City Area Code	888
Local Phone Number	319-6962
Title of 12(g) Security	Common Stock, $.002 par value per share
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 3,258,720
Entity Common Stock, Shares Outstanding		29,949,610
Auditor Firm ID	688
Auditor Name	Marcum LLP
Auditor Location	East Hanover, New Jersey

v3.23.2

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Sales, net	$ 50,672	$ 56,246
Cost of sales	46,611	49,694
Gross profit	4,061	6,552
Selling and administrative expenses	3,941	3,807
Operating income	120	2,745
Other income (expense), net:
Interest expense	(52)	(128)
Unrealized gain (loss) on investment in iBio Stock	27	(55)
Realized loss on sale of investment in iBio Stock	(35)	0
Other income	40	35
Total other income (expense), net	(20)	(148)
Income before income taxes	100	2,597
Income tax (expense) benefit, net	(134)	1,241
Net (loss) income	$ (34)	$ 3,838
Basic net (loss) income per common share (in dollars per share)	$ (0.00)	$ 0.13
Diluted net (loss) income per common share (in dollars per share)	$ (0.00)	$ 0.12
Weighted average common shares outstanding - basic (in shares)	29,949,610	29,843,386
Add: Equivalent shares outstanding - stock options (in shares)	0	2,477,939
Weighted average common shares outstanding - diluted (in shares)	29,949,610	32,321,326

v3.23.2

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Current Assets:
Cash	$ 1,316	$ 331
Accounts receivable, net	4,511	4,888
Inventories	10,261	11,055
Other current assets	284	352
Total current assets	16,372	16,626
Property and equipment, net	1,653	1,910
Operating lease right-of-use assets (includes $2,061 and $1,839 with a related party)	2,623	1,867
Deferred tax assets, net	4,726	4,798
Security deposits and other assets	57	49
Total Assets	25,431	25,250
Current Liabilities:
Advances under revolving credit facility	0	101
Accounts payable (includes $0 and $72 due to a related party)	2,266	3,209
Accrued expenses and other current liabilities	1,632	1,411
Current portion of long term debt, net	42	32
Current portion of operating lease liabilities	888	510
Total current liabilities	4,828	5,263
Long term debt, net	7	53
Operating lease liabilities	1,735	1,359
Total Liabilities	6,570	6,675
Commitments and Contingencies (Note 10)
Stockholders' Equity
Common Stock, $0.002 par value; 50,000,000 shares authorized; 29,984,510 and 29,949,610 shares issued and outstanding, respectively	60	60
Additional paid-in-capital	51,239	50,919
Accumulated deficit	(32,339)	(32,305)
Less: Treasury stock, at cost, 34,900 shares	(99)	(99)
Total Stockholders' Equity	18,861	18,575
Total Liabilities and Stockholders' Equity	$ 25,431	$ 25,250

v3.23.2

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Operating lease right-of-use assets	$ 2,623	$ 1,867
Accounts payable (includes $0 and $72 due to a related party)	2,266	3,209
Current portion of operating lease liabilities	888	510
Operating lease liabilities	$ 1,735	$ 1,359
Common stock, par value (in dollars per share)	$ 0.002	$ 0.002
Common stock, authorized (in shares)	50,000,000	50,000,000
Common stock, issued (in shares)	29,984,510	29,984,510
Common stock, outstanding (in shares)	29,949,610	29,949,610
Treasury Stock, Common, Shares	34,900	34,900
Vitamin Realty LLC [Member]
Operating lease right-of-use assets	$ 2,061	$ 1,839
Accounts payable (includes $0 and $72 due to a related party)	0	72
Current portion of operating lease liabilities	772	503
Operating lease liabilities	$ 1,289	$ 1,338

v3.23.2

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Total
Balance (in shares) at Jun. 30, 2021	29,838,177			34,900
Balance at Jun. 30, 2021	$ 60	$ 50,516	$ (36,143)	$ (99)	$ 14,334
Compensation expense for employee stock options	$ 0	369	0	$ 0	$ 369
Exercised (in shares)	146,333			0	146,333
Shares issued upon exercise of stock options	$ 0	34	0	$ 0	$ 34
Net (loss) income	0	0	3,838	0	3,838
Net income (loss)	$ 0	0	3,838	$ 0	3,838
Balance (in shares) at Jun. 30, 2022	29,984,510			34,900
Balance at Jun. 30, 2022	$ 60	50,919	(32,305)	$ (99)	18,575
Compensation expense for employee stock options	0	320	0	0	$ 320
Exercised (in shares)					0
Net (loss) income	0	0	(34)	0	$ (34)
Net income (loss)	$ 0	0	(34)	$ 0	(34)
Balance (in shares) at Jun. 30, 2023	29,984,510			34,900
Balance at Jun. 30, 2023	$ 60	$ 51,239	$ (32,339)	$ (99)	$ 18,861

v3.23.2

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net (loss) income	$ (34)	$ 3,838
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Amortization of operating lease right-of-use assets	803	498
Depreciation and amortization	351	336
Deferred income taxes (benefit)	72	(1,530)
Accretion of financing instruments, amortization of prepaid financing costs and other	12	21
Compensation expense on employee stock options	320	369
Unrealized (gain) loss on investment in iBio Stock	(27)	55
Realized loss on sale of iBio Stock	35	0
Bad debt expense	3	13
Gain on disposal of fixed assets	(1)	(22)
Changes in operating assets and liabilities:
Accounts receivable	374	875
Inventories	794	640
Prepaid expenses and other assets	34	(84)
Operating lease obligations	(804)	(501)
Accounts payable	(921)	(218)
Accrued expenses and other current liabilities	221	(199)
Net cash provided by operating activities	1,232	4,091
Cash flows from investing activities:
Purchase of property and equipment	(116)	(486)
Proceeds from sale of iBio Stock	4	0
Proceeds from sale of fixed assets	1	21
Net cash used in investing activities	(111)	(465)
Cash flows from financing activities:
Repayments of advances under revolving credit facility, net	(101)	(2,073)
Proceeds from exercises of stock options	0	34
Repayments under term notes payable	0	(1,466)
Repayments under financed lease obligations	(35)	0
Net cash used in financing activities	(136)	(3,505)
Net increase in cash	985	121
Cash at beginning of fiscal year	331	210
Cash at end of fiscal year	1,316	331
Supplemental disclosures of cash flow information:
Interest	41	113
Income taxes	0	471
Supplemental disclosures of non-cash transactions:
Amount owed on purchase of fixed assets	0	22
Financing on financed lease obligation	0	85
Acquisition of right-of-use asset, net and operating lease obligations, net	1,560	0
Trade in value on like-kind exchanges	$ 0	$ 7

v3.23.2

Note 1 - Business	12 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Business                                                Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States and Luxembourg. The Company was originally incorporated in the state of Delaware on August 31, 1995 under the name Chem International, Inc., on December 5, 2000, changed its name to Integrated Health Technologies, Inc. and, on January 29, 2003, changed its name to Integrated BioPharma, Inc.  The Company restated its certificate of incorporation in Delaware in June 2006.  The Company continues to do business as Chem International, Inc. with certain of its customers and certain vendors.   The Company’s business segments include: (a) Contract Manufacturing operated by Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers and (b) Other Nutraceutical Businesses which includes the operations of (i) AgroLabs, Inc. (“AgroLabs”), which distributed healthful nutritional products for sale through major mass market, grocery and drug and vitamin retailers, under the following brands: Peaceful Sleep, Wheatgrass and other products introduced into the market using the AgroLabs name (these are referred to as our branded products), (ii) The Vitamin Factory (the “Vitamin Factory”), which did sell private label MDC products, as well as our AgroLabs products, through the Internet, (iii) IHT Health Products, Inc. (“IHT”) a distributor of fine natural botanicals, including multi minerals produced under a license agreement, (iv) MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfillment services and (v) Chem International, Inc. (“Chem”), a distributor of certain raw materials for DSM Nutritional Products LLC.  The Vitamin Factory had no products available for sale and AgroLabs had no sales of its branded products in the fiscal years ended June 30, 2023 and 2022.

v3.23.2

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2. Summary of Significant Accounting Policies   Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation.   Reclassifications. Certain prior year amounts have been reclassified to conform to the current year presentation.   Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The most significant estimates include:   ●    sales returns and allowances; ●    allowance for doubtful accounts; ●    inventory valuation; ●    valuation and recoverability of long-lived assets; ●    income taxes and valuation allowance on deferred income taxes, and; ●    accruals for, and the probability of, the outcome of current litigation, if any.   On a continual basis, management reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.         Revenue Recognition. The Company recognizes product sales revenue, the prices of which are fixed and determinable, when title and risk of loss have transferred to the customer, when estimated provisions for product returns, rebates, charge-backs and other sales allowances are reasonably determinable, and when collectability is reasonably assured. Accruals for these items are presented in the consolidated financial statements as reductions to sales. The Company’s net sales represent gross sales invoiced to customers, less certain related charges for discounts, returns, rebates, charge-backs and other allowances. Cost of sales includes the cost of raw materials and all labor and overhead associated with the manufacturing and packaging of the products. Gross margins are affected by, among other things, changes in the relative sales mix among our products and valuation and/or charge off of slow moving, expired or obsolete inventories. To perform revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps:     ● identification of the promised goods or services in the contract;   ● determination of whether the promised goods or serves are performance obligations including whether they are distinct in the context of the contract;   ● measurement of the transaction price, including the constraint on variable consideration;   ● allocation of the transaction price to the performance obligations based on estimated selling prices; and   ● recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise to transfer a distinct good or service to the customer and is the unit of account in ASC 606.   Shipping and Handling Costs. Shipping and handling costs were approximately $1,006 and $349 for the fiscal years ended June 30, 2023 and 2022, respectively, and are included in cost of sales in the accompanying Consolidated Statements of Operations.   Stock-Based Compensation. The Company has two stock-based compensation plans that have outstanding options issued in accordance with such plans. The Company periodically grants stock options to employees and directors in accordance with the provisions of its stock option plans, with the exercise price of the stock options being set at the closing market price of the common stock on the date of grant. Stock based compensation expense is recognized based on the estimated fair value, utilizing a Black-Scholes option pricing model, of the instrument on the date of grant over the requisite vesting period, which is generally three years.   Income Taxes. The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will not be realized.   The Company files a U.S. federal income tax return as well as returns for various states. The Company’s income taxes have not been examined by any tax authorities for the periods subject to review by such taxing authorities, except for the State of New Jersey tax filings for MDC and CII which were reviewed by the State of New Jersey for the then open tax periods of 2014 through 2017 and 2016 to 2019, respectively.  Uncertain tax positions, if any, taken on our tax returns are accounted for as liabilities for unrecognized tax benefits. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the Consolidated Statements of Operations. There were no liabilities recorded for uncertain tax positions at June 30, 2023 or 2022.       Leases. We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities on our consolidated balance sheets.   The ROU assets related to Finance leases are included in property and equipment on our consolidated statement of financial condition.    Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.   We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component.   Earnings Per Share. Basic earnings per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, subject to anti-dilution limitations using the treasury stock method.   Fair Value of Financial Instruments. Generally accepted accounting principles require disclosing the fair value of financial instruments to the extent practicable for financial instruments which are recognized or unrecognized in the balance sheet. The fair value of the financial instruments disclosed herein is not necessarily representative of the amount that could be realized or settled, nor does the fair value amount consider the tax consequences of realization or settlement.   In assessing the fair value of financial instruments, the Company uses a variety of methods and assumptions, which are based on estimates of market conditions and risks existing at the time. For certain instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, it was estimated that the carrying amount approximated fair value because of the short maturities of these instruments. All debt is based on current rates at which the Company could borrow funds with similar remaining maturities and approximates fair value.   Accounts Receivable and Allowance for Doubtful Accounts. In the normal course of business, the Company extends credit to customers. Accounts receivable, less the allowance for doubtful accounts, reflect the net realizable value of receivables, and approximate fair value. The Company believes there is no concentration of credit risk with any single customer whose failure or nonperformance would materially affect the Company’s results other than as discussed in Note 9(c) – Significant Risks and Uncertainties – Major Customers. On a regular basis, the Company evaluates its accounts receivables and establishes an allowance for doubtful accounts based on a combination of specific customer circumstances, credit conditions, and historical write-offs and collections. The allowance for doubtful accounts as of June 30, 2023 and 2022 was $37 and $85, respectively. Accounts receivable are charged off against the allowance after management determines that the potential for recovery is remote.   Inventories. Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. Allowances for obsolete and overstock inventories are estimated based on “expiration dating” of inventory and projection of sales.     Property and Equipment. Property and equipment are recorded at cost and are depreciated using the straight line method over the following estimated useful lives:   Building 15 Years Leasehold Improvements    Shorter of estimated useful life or term of lease Machinery and Equipment   7 Years Transportation Equipment 5 Years                       Impairment of Long-Lived Assets. Long-lived assets are reviewed for impairment when circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows estimated by the Company to be generated by such assets. If such assets are considered to be impaired, the impairment to be recognized is the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of by sale are recorded as held for sale at the lower of carrying value or estimated net realizable value. Tests for impairment or recoverability are performed at least annually and require significant management judgment and the use of estimates which the Company believes are reasonable and appropriate at the time of the impairment test. Future unanticipated events affecting cash flows and changes in market conditions could affect such estimates and result in the need for an impairment charge. The Company also re-evaluates the periods of amortization to determine whether circumstances warrant revised estimates of current useful lives. No impairment losses were identified or recorded in the fiscal years ended June 30, 2023 and 2022 on the Company’s long-lived assets.   Investment in iBio, Inc. Prior to the adoption of ASU 2016-01 on July 1, 2018, the Company accounted for its investment in iBio, Inc. (“iBio”) common stock on the cost basis as it retained approximately 6% of its interest in iBio (the “iBio Stock”) at the time of the spin-off of this subsidiary in August 2008.  The Company reviewed its investment in iBio for impairment and recorded a loss when there was deemed to be a permanent impairment of the investment.  To date, there were cumulative impairment charges of approximately $2,562. ASU 2016-01, requires equity investments to be measured at fair value and recognize changes in fair value in net income.  During the year ended June 30, 2023 and 2022, the Company recognized realized losses of $35 and $0, respectively and unrealized gain (loss) of $27 and $(55) for the fiscal years ended June 30, 2023 and 2022, respectively.  As of June 30, 2023, the Company no longer owns any iBio Stock and as of June 3, 2022, the market value of the iBio Stock was approximately $12, based on the trade price at the close of trading on June 30, 2022.  The investment in iBio is included in other current assets in the consolidated balance sheets as of June 30, 2022 at the respective market value.   Accounting Pronouncements Adopted   In June 2016, the FASB issued ASU 2016-13 “Financial Instruments-Credit Losses-Measurement of Credit Losses on Financial Instruments”. This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance applies to loans, accounts receivable, trade receivables and other financial assets measured at amortized cost, loan commitments, debt securities and beneficial interests in securitized financial assets, but the effect on the Company is projected to be limited to accounts receivable. The guidance was effective for the fiscal year beginning on July 1, 2023, including interim periods within that year. The adoption of this standard did not have a material impact on the Company’s Consolidated Financial Statements.   In May 2019, the FASB issued ASU 2021-05 “Financial Instruments-Credit Losses (Topic 326)” which provides transition relief for companies adopting ASU 2016-13. This guidance amends ASU 2016-13 to allow companies to elect, upon adoption of ASU 2016-13, the fair value option on financial instruments that were previously recorded at amortized cost under certain circumstances. Companies are required to make this election on and instrument by instrument basis. The guidance will be effective for the fiscal year beginning on July 1, 2023, including interim periods within that year. The adoption of this standard did  not have a material impact on the Company’s Consolidated Financial Statements.     In October 2021, the FASB issued ASU 2021-10, Codification Improvements.  The guidance contains improvements to the Codification by ensuring that all guidance that requires or provides an option or an entity to provide information in the notes to the financial statements is codified in the Disclosure Section of the Codification.  The guidance also contains Codifications that are varied in nature and may affect the application of the guidance in cases in which the original guidance may have been unclear.  For public business entities, the amendments in the ASU are effective for annual periods beginning after December 15, 2022, and interim periods within annual periods beginning after December 15, 2023.  The adoption of ASU 2021-10 did not have a material impact on its consolidated financial statements.

v3.23.2

Note 3 - Inventories	12 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 3. Inventories   Inventories are stated at the lower of cost or net realizable value using the first-in, first-out method and consist of the following:       June 30,       2023     2022                     Raw materials   $ 6,859     $ 7,586   Work-in-process     2,148       1,759   Finished goods     1,254       1,440   Total   $ 10,261     $ 11,055

v3.23.2

Note 4 - Property and Equipment, Net	12 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 4. Property and Equipment, net   Property and equipment consists of the following:       June 30,       2023     2022                     Land and building   $ 1,250     $ 1,250   Leasehold improvements     1,371       1,371   Machinery and equipment     6,801       6,727   Transportation equipment     -       6         9,422       9,354   Less:  Accumulated depreciation and amortization     (7,769 )     (7,444 ) Total   $ 1,653     $ 1,910     Depreciation and amortization expense was $351 and $336 for the fiscal years ended June 30, 2023 and 2022, respectively.  Additionally, the Company disposed of fully depreciated property of $26 and $309 in the fiscal years ended June 30, 2023 and 2022, respectively.  The Company also recognized a net gain on disposals of $0 and $2 on property, including property in the aggregate amount of $0 and $16 that were not fully depreciated and a gain on the sale of equipment of $1 and $20 in the fiscal years ended June 30, 2023 and 2022, respectively.

v3.23.2

Note 5 - Senior Credit Facility and Other Long Term Debt	12 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 5. Senior Credit Facility   As of June 30, 2023 and 2022, the Company had the following debt outstanding:       Principal Amount     Interest Rate   Maturity Date     June 30,                 2023     2022             Revolving advances under Senior Credit Facility with PNC Bank, National Association   $ -     $ 101       8.25 % 5/15/2024 Total outstanding debt   $ -     $ 101               SENIOR CREDIT FACILITY   On March 16, 2023, the Company, MDC, AgroLabs, IHT, IHT Properties Corp. (“IHT Properties”) and Vitamin Factory (collectively, the “Borrowers”) amended the Revolving Credit, Term Loan and Security Agreement (the “Amended Loan Agreement”) with PNC Bank, National Association as agent and lender (“PNC”) and the other lenders party thereto entered into on June 27, 2012, as amended on February 19, 2016 and May 15, 2019.   The Amended Loan Agreement provides for a total of $11,585 in senior secured financing (the “Senior Credit Facility”) as follows: (i) discretionary advances (“Revolving Advances”) based on eligible accounts receivable and eligible inventory in the maximum amount of $8,000 (the “Revolving Credit Facility”), and (ii) a term loan in the amount of $3,585 (the “Term Loan”). The Senior Credit Facility is secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and common stock of iBio owned by the Company.  Revolving Advances bear interest at PNC’s Base Rate (8.25% and 4.75% as of June 30, 2023 and 2022, respectively) or the Eurodollar Rate, at Borrowers’ option, plus 2.50%. The Term Loan bore interest at PNC’s Base Rate (5.00% as of June 30, 2022) or the Eurodollar Rate at Borrowers’ option, plus 3.00%. As of September 15, 2023, the Revolving Advance interest rate is 8.50%.   As of March 16, 2023, the Amended Loan Agreement provides that any loans, advances and/or other extensions of credit denominated in U.S. Dollars prior to March 16, 2023 that bear interest or are permitted to bear interest, and have fees, commissions or other  amounts based on the London Interbank Offered Rate administered by the ICE Benchmark Administration (which may be referred to as the “Eurodollar Rate” ( “LIBOR”) shall thereafter bear interest based on the Term SOFR Rate plus the SOFR Adjustment . The Term SOFR Rate, for any day, shall be equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate). The SOFR Adjustment is defined as 10 basis points (0.10%).   Upon and after the occurrence of any event of default under the Amended Loan Agreement, and during the continuation thereof, interest shall be payable at the interest rate then applicable plus 2%. The Senior Credit Facility matures on May 15, 2024 (the “Senior Maturity Date”).   The principal balance of the Revolving Advances is payable on the Senior Maturity Date, subject to acceleration, based upon a material adverse event clause, as defined, subjective accelerations for borrowing base reserves, as defined or upon the occurrence of any event of default under the Amended Loan Agreement or earlier termination of the Amended Loan Agreement pursuant to the terms thereof. The Term Loan shall be repaid in eighty-four (84) consecutive monthly installments of principal, the first eighty-three (83) of which shall be in the amount of $43, commencing on the first business day of June 2019, and continuing on the first business day of each month thereafter, with a final payment of any unpaid balance of principal and interest payable on the Senior Maturity Date. The foregoing is subject to customary mandatory prepayment provisions and acceleration upon the occurrence of any event of default under the Amended Loan Agreement or earlier termination of the Amended Loan Agreement pursuant to the terms thereof.  The Company satisfied all the principal payments required under the Term Note on January 3, 2022.      The Revolving Advances are subject to the terms and conditions set forth in the Amended Loan Agreement and are made in aggregate amounts at any time equal to the lesser of (x) $8,000 or (y) an amount equal to the sum of: (i) up to 85%, subject to the provisions in the Amended Loan Agreement, of eligible accounts receivables (“Receivables Advance Rate”), plus (ii) up to the lesser of (A) 75%, subject to the provisions in the Amended Loan Agreement, of the value of the eligible inventory (“Inventory Advance Rate” and together with the Receivables Advance Rate, collectively, the “Advance Rates”), (B) 85% of the appraised net orderly liquidation value of eligible inventory (as evidenced by the most recent inventory appraisal reasonably satisfactory to PNC in its sole discretion exercised in good faith) and (C) the inventory sublimit in the aggregate at any one time (“Inventory Advance Rate” and together with the Receivables Advance Rate, collectively, the “Advance Rates”), minus (iii) the aggregate Maximum Undrawn Amount, as defined in the Amended Loan Agreement, of all outstanding letters of credit, minus (iv) such reserves as PNC may reasonably deem proper and necessary from time to time.   The Amended Loan Agreement contains customary mandatory prepayment provisions, including, without limitation the requirement to use any sales proceeds from the sale of iBio Stock to repay the Term Loan and to prepay the outstanding amount of the Term Note in an amount equal to twenty-five percent (25%) of Excess Cash Flow, as defined in the Amended Load Agreement, for each fiscal year commencing with the fiscal year ended June 30, 2016, payable upon delivery of the financial statements to PNC referred to in and required by the Amended Loan Agreement for such fiscal year but in any event not later than one hundred twenty (120) days after the end of each such fiscal year, which amount shall be applied ratably to the outstanding principal installments of the Term Loan in the inverse order of the maturities thereof. The Amended Loan Agreement also contains customary representations and warranties, covenants and events of default, including, without limitation, (i) a fixed charge coverage ratio maintenance requirement and (ii) an event of default tied to any change of control as defined in the Amended Loan Agreement.  As of June 30, 2023, the Company was in compliance with the fixed charge coverage ratio maintenance requirement, with the required annual payments of 25% of the Excess Cash Flow for each fiscal year commencing with the fiscal year ended June 30, 2016 and used the proceeds of $96 from the sale of iBio Stock in the fiscal year ended June 30, 2021, to repay the Term Loan.  Additionally, with the required annual payment of 25% of Excess Cash Flow for the fiscal year ended June 30, 2021, together with the required monthly installments of $43, the Company satisfied all the remaining principal payments required under the Term Note on January 3, 2022.   In connection with the Senior Credit Facility, the following loan documents were executed: (i) a Stock Pledge Agreement with PNC, pursuant to which the Company pledged to PNC the iBio Stock; (ii) a Mortgage and Security Agreement with PNC with IHT Properties; and (iii) an Environmental Indemnity Agreement with PNC.

v3.23.2

Note 6 - Interest Expense	12 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Interest Expense [Text Block]	Note 6. Interest Expense   The components of interest expense for the fiscal years ended June 30, 2023 and 2022 are presented below:       For the Fiscal Year Ended June 30,       2023     2022                     Interest on Senior Debt   $ 40     $ 103   Amortization of prepaid financing costs     12       21   Other interest expense     -       4   Interest Expense   $ 52     $ 128     The weighted average interest rate paid was 5.67% and 3.33% in the fiscal years ended June 30, 2023 and 2022, respectively. As of June 30, 2023 and 2022, the Company had accrued unpaid interest of approximately $0 and $3, respectively.

v3.23.2

Note 7 - Income Taxes	12 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 7. Income Taxes   The components of the provision for income taxes consists of the following:         For the fiscal year       ended June 30,       2023     2022                     Current - Federal tax expense   $ (110 )   $ (600 ) Current - State tax expense     (61 )     (289 ) Deferred - Federal benefit     55       2,106   Deferred - State tax (expense) benefit     (18 )     24   Income tax (expense) benefit, net   $ (134 )   $ 1,241     A reconciliation of the statutory tax rate to the effective tax rate is as follows:         For the fiscal year       ended June 30,       2023     2022   Statutory federal income tax rate     (21.0 )%     (21.0 )% State income tax rate     (55.1 )%     (11.5 )% Stock compensation     (166.0 )%     (4.6 )% Change in valuation allowance     201.2 %     85.6 % Other temporary differences     (62.1 )%     (0.6 )% Loss on sale of iBio Stock     (18.4 )%     -   Non-deductible expenses     (12.6 )%     (0.1 )% Effective income tax rate     (134 )%     47.8 %       Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial accounting purposes and the amounts used for income tax reporting. Significant components of the Company’s net deferred tax assets are as follows:       June 30,       2023     2022   Deferred Tax Assets                 Net operating loss   $ 5,105     $ 5,166   Capital loss carryover     678       485   Depreciation     (139 )     (157 ) Inventory     180       149   Other     337       296   Valuation allowance     (1,435 )     (1,141 ) Total deferred tax asset, net   $ 4,726     $ 4,798     The Company has net operating losses (“NOL”) of approximately $21,700 for federal purposes which expire beginning in 2028, which were federal NOLs generated prior to 2018.  NOLs generated post 2018 have an indefinite life, subject to 80% of taxable income, there were no NOLs generated post 2018.  State NOL’s of approximately $3,997 expire beginning in 2031 through 2039. The Company also has capital loss carryforwards of $2,343 of which $271, $1,152 and $920 will expire in 2025,   2026 and 2028, respectively. The Company files a consolidated U.S. federal income tax return; however, the various state tax returns were filed on a stand-alone basis for the Company and its subsidiaries until the fiscal year ended June 30, 2021, which state income tax return are now filed on a combined basis. MDC has fully utilized its state NOL’s resulting in taxable income on a state level basis for the combined group.    Realization of the NOL carryforwards and other deferred tax temporary differences is contingent on future taxable earnings. The Company’s deferred tax asset was reviewed for expected utilization using a “more likely than not” approach by assessing the available positive and negative evidence surrounding its recoverability. Accordingly, a valuation allowance has been recorded against the Company’s deferred tax asset, as it was determined based upon past taxable losses and inconsistent taxable income in the past few years, that it was “more likely than not” that the Company’s deferred tax assets would not be realized. As of June 30, 2022, management determined that certain of the Company’s deferred tax assets were “more likely than not” to be realizable and the Company recognized deferred tax benefits related to the release of the valuation allowance on those assets of approximately $1,795.   The Company will continue to assess and evaluate strategies that will enable the deferred tax asset, or portion thereof, to be utilized, and will reduce the valuation allowance appropriately at such time when it is determined that the “more likely than not” criteria is satisfied.   There were no significant uncertain tax positions taken, or expected to be taken, in a tax return that would be determined to be an unrecognized tax benefit taken or expected to be taken in a tax return that should have been recorded on the Company’s consolidated financial statements for the year ended June 30, 2023.  Additionally, there were no interest or penalties outstanding as of or for each of the fiscal years ended June 30, 2023 and 2022.   The latest three years of Federal and four years of state tax returns filed for the fiscal years ended through June 30, 2023 are currently open except for the State of New Jersey tax filings for CII which have been reviewed for the tax period of 2019. The tax returns for the year ended June 30, 2023 will be filed by March 15, 2024.

v3.23.2

Note 8 - Profit-sharing Plan	12 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Retirement Benefits [Text Block]	Note 8. Profit-Sharing Plan   The Company maintains a profit-sharing plan, which qualifies under Section 401(k) of the Internal Revenue Code, covering all nonunion employees meeting age and service requirements. Contributions are determined by matching a percentage of employee contributions. For the fiscal years ended June 30, 2023 and 2022, the Company contributed approximately $81 and $86, respectively, into the plan for the benefit of the eligible employees participating in the plan.

v3.23.2

Note 9 - Significant Risks and Uncertainties	12 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 9. Significant Risks and Uncertainties   (a) Concentrations of Credit Risk-Cash. The Company maintains balances at several financial institutions. Deposits at each institution are insured by the Federal Deposit Insurance Corporation up to $250. As of June 30, 2023, the Company had $1,949 in uninsured deposits at these financial institutions.   (b) Concentrations of Credit Risk-Receivables. The Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk of its customers, establishes an allowance for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowances is limited. The Company does not require collateral in relation to its trade accounts receivable credit risk.   (c) Major Customers.  In the fiscal years ended June 30, 2023 and 2022, approximately 89% and 90% of consolidated net sales, respectively, were derived from two customers. These two customers are in the Company’s Contract Manufacturing Segment and represent approximately 70% and 24% and 67% and 26%, respectively, of this segment’s net sales in the fiscal years ended June 30, 2023 and 2022, respectively.  Accounts receivable from these two major customers represented approximately 84% and 70% of total net accounts receivable as of June 30, 2023 and 2022, respectively.  Three other customers in the Other Nutraceutical Segment, while not significant customers of the Company’s consolidated net sales, represented approximately 56%, 16% and 9% and 40%, 1% and 19%, respectively, of net sales of the Other Nutraceutical Segment in the fiscal years ended June 30, 2023 and 2022, respectively.  The loss of any of these customers could have an adverse effect on the Company’s operations. Major customers are those customers who account for more than 10% of net sales.   (d) Business Risks. The Company insures its business and assets against insurable risks, to the extent that it deems appropriate, based upon an analysis of the relative risks and costs. The Company believes that the risk of loss from non-insurable events would not have a material adverse effect on the Company’s operations as a whole.   The raw materials used by the Company are primarily commodities and agricultural-based products. Raw materials used by the Company in the manufacture of its nutraceutical products are purchased from independent suppliers. Raw materials are available from numerous sources and the Company believes that it will continue to obtain adequate supplies.   As of June 30, 2023, approximately 74% the Company’s employees are covered by a union contract and are employed in its New Jersey facilities. The contract was renewed effective September 1, 2022 and will expire on August 31, 2026.   While the Company hasn’t, to date, seen a significant negative impact in its margins resulting from the coronavirus outbreak, it is experiencing a negative impact on its margins due to inflation and tightened labor markets.  The Company may not be able to timely increase its selling prices to its customer resulting from price increases from its suppliers due to various economic factors, including inflation, labor and shipping costs and its own increases in shipping, labor and other operating costs. The Company’s results of operations may also be affected by economic conditions, including inflationary pressures, that can impact consumer disposable income levels and spending habits, thereby reducing the orders it may receive from the Company’s significant customers.     The Company continues to experience minimal supply chain disruptions relating to fuel refinery and transportation issues as it pertains to shipping.  These issues first arose as result of the COVID-19 pandemic and other geo-political events. The significant outbreak of this contagious disease in the human population has resulted in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could affect demand for the Company’s products and impact the Company’s operating results.   During the first quarter of calendar 2022, the war in Ukraine affected the Company’s customer’s business operations in Ukraine and Russia, resulting in the cancelation of some future orders. The war resulted in the imposition of sanctions by the United States, the United Kingdom, and the European Union, that affect the cross-border operations of businesses operating in Russia. In addition, many multinational companies ceased or suspended their operations in Russia. Therefore, the ability to continue operations in Russia by the Company’s customers is uncertain.  Also, there may be a shortage of Sunflower Oil products in the near future and this may cause delays in production of certain raw materials and may require reformulation of products.

v3.23.2

Note 10 - Commitments and Contingencies	12 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 10. Commitments and Contingencies   (a) Leases. The Company has operating and finance leases for its corporate and sales offices, warehousing and packaging facilities and certain machinery and equipment, including office equipment. The Company’s leases have remaining terms of less than 1 year to less than 7 years.   The components of lease expense for the fiscal year ended June 30, 2023 and 2022 were as follows:         2023     2022       Related Party - Vitamin Realty     Other Leases     Totals     Related Party - Vitamin Realty     Other Leases     Totals                                                     Operating Lease Costs   $ 842     $ 88     $ 650     $ 566     $ 84     $ 650                                                     Finance Operating Lease Costs:                                                 Amortization of right-of use assets   $ -     $ 12     $ 12     $ -     $ 3     $ 3   Total Finance Lease Costs   $ -     $ 12     $ 12     $ -     $ 3     $ 3     Rent and lease amortization costs are included in cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations.   Operating Lease Liabilities   Related Party Operating Lease Liabilities.  Warehouse and office facilities are leased from Vitamin Realty Associates, LLC (“Vitamin Realty”), which is 100% owned by the estate of the Company’s former chairman, and a major stockholder and certain of his family members, who are the Co-Chief Executive Officers and directors of the Company.  On January 5, 2012, MDC entered into a second amendment of lease (the “Second Lease Amendment”) with Vitamin Realty for its office and warehouse space in New Jersey increasing its rentable square footage from an aggregate of 74,898 square feet to 76,161 square feet and extending the expiration date to January 31, 2026.  This Second Lease Amendment provided for minimum annual rental payments of $533, plus increases in real estate taxes and building operating expenses.  On July 15, 2022, MDC entered into a third amendment of the lease (the “Third Lease Amendment”) with Vitamin Realty, increasing its rentable square footage to 116,175.  This Third Lease Amendment provided for minimum annual rental payments of $842, plus increases in real estate taxes and the building operating expenses allocation percentage and is effective as of July 1, 2022.         On May 19, 2014, AgroLabs entered into an amendment to the lease agreement entered into on January 5, 2012, with Vitamin Realty for an additional 2,700 square feet of warehouse space in New Jersey, the term of which was to expire on January 31, 2020 to extend the expiration date to June 1, 2024. This additional lease provided for minimum lease payments of $27 with annual increases plus the proportionate share of operating expenses.  The AgroLabs Lease was mutually terminated on July 15, 2022 with an effective date of July 1, 2022.   Rent expense, lease amortization costs and imputed interest costs on these related party leases were $1,269 and $896 for the fiscal years ended June 30, 2023 and 2022, respectively, and are included in cost of sales and selling and administrative expenses in the accompanying Consolidated Statements of Operations. As of June 30, 2023 and 2022, the Company had outstanding current obligations to Vitamin Realty of $0 and $72, respectively, included in accounts payable in the accompanying Consolidated Balance Sheets.  Additionally, as of June 30, 2023 and 2022, the Company has operating lease obligations of $2,061 and $1,841, respectively, with Vitamin Realty as noted in the accompany Consolidated Balance Sheet.   Other Operating Lease Liabilities. The Company has entered into certain non-cancelable operating lease agreements expiring up through May 2023, related to machinery and equipment and office equipment.    As of June 30, 2023, the Company’s ROU assets, lease obligations and remaining cash commitment on these leases is as follows:       Right-of-use Assets     Current Portion Operating Lease Obligations     Operating Lease Obligations     Remaining Cash Commitment                                     Vitamin Realty Leases   $ 2,061     $ 772     $ 1,289     $ 1,972   Warehouse Lease     541       108       433       631   Office equipment leases     21       8       13       23       $ 2,623     $ 888     $ 1,735     $ 2,830     As of June 30, 2022, the Company’s ROU assets, lease obligations and remaining cash commitment on these leases is as follows:       Right-of-use Assets     Current Portion Operating Lease Obligations     Operating Lease Obligations     Remaining Cash Commitment                                     Vitamin Realty Leases   $ 1,839     $ 503     $ 1,338     $ 1,972   Office equipment leases     28       7       21       32       $ 1,867     $ 510     $ 1,359     $ 2,004     As of June 30, 2023 and 2022, the Company’s weighted average discount rate is 4.41% and 3.87%, for the fiscal years then ended, respectively, and the remaining term on lease liabilities is approximately 2.9 years and 3.5 years, respectively.       Financed Lease Obligation.    On June 15, 2022, the Company entered into a financed lease obligation with LEAF Capital Funding, LLC in the amount of $85, which lease is secured by certain machinery and equipment and matures on August 15, 2024.  The lease payment in the amount of approximately $4 is payable monthly, beginning September 15, 2023 and has a stated interest rate of 0.0%.   As of each June, 2023 and 2022, the Company’s weighted average discount rate for the outstanding finance lease obligation is 0% and the remaining term on finance lease obligation is approximately 1.2 years and 2.2 years, respectively.  The ROU asset related to the finance lease obligation is included in Property and equipment, net in the accompanying Consolidated Balance Sheet.   Supplemental cash flows information related to leases for the fiscal year ended June 30, 2023 is as follows:         Related Party - Vitamin Realty     Other Leases     Totals                             Cash paid for amounts included in the measurement of lease liabilities:                                                   Operating cash flows from operating leases   $ 842     $ 147     $ 989   Operating cash flows from finance lease obligations     -       -       -   Financing cash flows from finance lease obligations     -       35       35       Supplemental cash flows information related to leases for the fiscal year ended June 30, 2022 is as follows:         Related Party - Vitamin Realty     Other Leases     Totals                             Cash paid for amounts included in the measurement of lease liabilities:                                                   Operating cash flows from operating leases   $ 566     $ 84     $ 650   Operating cash flows from finance lease obligations     -       -       -   Financing cash flows from finance lease obligations     -       -       -       In the fiscal year ended June 30, 2023, in addition to the Third Amendment with Vitamin Realty the Company renewed, for one year, an operating lease for office space with an annual commitment of $10 and entered into a five year lease for additional warehouse space of 12,500 square feet with an annual commitment of $134 in the first year increasing to $150 in the fifth year of the lease (the “Warehouse Lease”).  The Warehouse Lease includes additional rent of not less than $1 per month for the Company’s pro rata portion of the lessor’s operating expenses and commenced on December 1, 2022.  Additionally, on August 4, 2023, the Company entered into a four year operating lease for transportation equipment with an annual commitment of $21.       Maturities of operating lease liabilities as of June 30, 2023 were as follows:     Year ending June 30,   Operating Lease Commitment     Related Party Operating Lease Commitment     Finance Lease Obligation     Total                                     2024   $ 146     $ 842     $ 42     $ 1,030   2025     149       842       7       998   2026     148       492       -       640   2027     148       -       -       148   2028     63       -       -       63   Total minimum lease payments     654       2,176       49       2,879   Imputed interest     (92 )     (115 )     -       (207 ) Total   $ 562     $ 2,061     $ 49     $ 2,672       (b) Legal Proceedings.   The Company is subject, from time to time, to claims by third parties under various legal theories. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.

v3.23.2

Note 11 - Related Party Transactions	12 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 11. Related Party Transactions   See Note 10(a) - Leases for related party lease transactions.

v3.23.2

Note 12 - Equity Transactions and Stock-based Compensation	12 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Equity [Text Block]	Note 12. Equity Transactions and Stock-Based Compensation   Stock Option Plans. The Company has adopted a stock option plan for the granting of options or restricted shares to employees, officers, directors and consultants of the Company that originally provided for the issuance of up to 7,000,000 shares of common stock, at the discretion of the Board of Directors. Subsequent to the adoption, the Board of Directors and stockholders approved additional common stock shares aggregating 6,000,000 to be available for grant, for a total of 13,000,000 shares of common stock reserved for issuance under the Company’s 2001 Stock Option Plan, as amended (the “Plan”). The Company also has a 1997 Stock Option Plan with 5,000,000 shares of common stock reserved for issuance. Stock option grants may not be priced less than the fair market value of the Company’s common stock at the date of grant. Options granted are generally for ten-year periods, except that incentive stock options granted to a 10% stockholder (as defined) are limited to five-year terms. As of June 30, 2023, the Company has 6,823,569 shares of common stock remaining under the Plans.   In the fiscal year ended June 30, 2023, the Board of Directors authorized the issuance of up to 538,500 stock options to Company officers and employees. The Company issued 527,000 stock options with an exercise price ranging from $0.41 to $0.45, vesting over three years, with expiration terms of either five or ten years from the date of grant.  For the fiscal years ended June 30, 2023 and 2022, the Company incurred stock-based compensation expense of $320 and $369, respectively.  The Company expects to record additional stock-based compensation of $480 over the remaining estimated vesting period of approximately two and half years.    In July 2023, the Board of Directors authorized the issuance of 200,000 stock options to the non-executive directors of (50,000 each) with an exercise price of $0.33, vesting over one year, 25% at the end of each quarter ending September 30, 2023, December 21, 2023, March 31, 2024 and June 30, 2024.           The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during the year ended June 30, 2023:   Risk Free Interest Rate     3.85% to 3.00 % Volatility     103.3% to 116.9 % Term     4.5 to 7.5 years   Dividend Rate     0.00 % Closing Price of Common Stock   $ 0.41     The Company calculates expected volatility for a stock-based grant based on historic daily stock price observations of its common stock during the period immediately preceding the grant that is equal in length to the expected term of the grant. The expected term of the options is estimated based on the Company’s historical exercise rate and forfeiture rates are estimated based on employment termination experience. The risk free interest rate is based on U.S. Treasury yields for securities in effect at the time of grants with terms approximating the term of the grants. The assumptions used in the Black-Scholes option valuation model are highly subjective, and can materially affect the resulting valuations.   In the fiscal year ended June 30, 2022, the Board of Directors authorized the issuance of 764,700 stock options to Company officers, employees and directors with an exercise price of $0.51, $0.95 or $1.045, vesting over one or three years, with terms of either five or ten years.   In the fiscal years ended June 30, 2023 and 2022, stock options in the aggregate amount of 4,376,284 and 537,600, were not included in the computation of weighted average diluted common shares outstanding as the effect of doing so would have been anti-dilutive.   The intrinsic value of options outstanding and exercisable at June 30, 2023 and 2022 was $461 and $1,002, respectively.   A summary of the Company’s stock option activity, and related information for the years ended June 30, follows:               Weighted               Average               Exercise       Options     Price                     Outstanding as of July 1, 2021     3,916,666     $ 0.26   Granted     764,700       0.85   Exercised     (146,333 )     0.23   Terminated     (44,700 )     0.53   Expired     (46,400 )     0.47   Outstanding as of June 30, 2022     4,443,933       0.36   Granted     527,000       0.42   Exercised     -       -   Terminated     -       -   Expired     (594,649 )     0.46   Outstanding as of June 30, 2023     4,376,284     $ 0.35                     Exercisable at June 30, 2022     3,524,500     $ 0.26   Exercisable at June 30, 2023     3,626,551     $ 0.30         The following table summarizes the range of exercise prices and weighted-average exercise prices for stock options outstanding and exercisable as of June 30, 2023 under the Company’s stock option plans:                                                                          Weighted                     Weighted   Weighted Average       Average             Average   Remaining       Exercise   Range of Exercise Price   Outstanding   Exercise Price   Contractual Life (years) Exercisable   Price                                         $ 0.09 - $ 0.10     1,221,000   $ 0.09   1.9   1,296,000   $ 0.09   $ 0.21 - $ 0.21     1,194,000     0.21   5.9   1,209,000     0.21   $ 0.23 - $ 0.25     250,000     0.23   3.4   250,000     0.23   $ 0.41 - $ 0.41     426,500     0.41   9.4   -     0.00   $ 0.51 - $ 0.51     200,000     0.51   9.0   200,000     0.51   $ 0.65 - $ 0.65     570,667     0.65   7.4   431,000     0.65   $ 0.72 - $ 0.72     66,667     0.72   0.7   66,667     0.72   $ 0.95 - $ 0.95     425,783     0.95   8.4   242,217     0.95   $ 1.05 - $ 1.05     21,667     1.05   0.7   21,667     1.05   $ 0.09 - $ 1.05     4,376,284   $ 0.35   7.0   3,626,551   $ 0.30

v3.23.2

Note 13 - Segment Information	12 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 13. Segment Information   The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments.   The Company has divided its operations into two reportable segments; Contract Manufacturing and Other Nutraceutical Businesses. The international sales, concentrated primarily in Europe, for the fiscal years ended June 30, 2023 and 2022 were $8,055 and $9,729, respectively.   Financial information relating to the fiscal years ended June 30, 2023 and 2022 operations by business segment are as follows:           Sales, Net     Segment                                 U.S.     International             Gross             Capital     Total         Customers     Customers     Total     Profit     Depreciation     Expenditures     Assets   Contract Manufacturing 2023   $ 40,230     $ 8,047     $ 48,277     $ 3,630     $ 348     $ 109     $ 19,507     2022     44,450       9,641       54,091       5,917       332       486       19,061                                                               Other Nutraceutical Businesses 2023     2,387       8       2,395       431       3       7       5,924     2022     2,067       88       2,155       635       4       -       6,189                                                               Total Company 2023     42,617       8,055       50,672       4,061       351       116       25,431     2022     46,517       9,729       56,246       6,552       336       486       25,250

v3.23.2

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation.
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications. Certain prior year amounts have been reclassified to conform to the current year presentation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The most significant estimates include:   ●    sales returns and allowances; ●    allowance for doubtful accounts; ●    inventory valuation; ●    valuation and recoverability of long-lived assets; ●    income taxes and valuation allowance on deferred income taxes, and; ●    accruals for, and the probability of, the outcome of current litigation, if any.   On a continual basis, management reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition. The Company recognizes product sales revenue, the prices of which are fixed and determinable, when title and risk of loss have transferred to the customer, when estimated provisions for product returns, rebates, charge-backs and other sales allowances are reasonably determinable, and when collectability is reasonably assured. Accruals for these items are presented in the consolidated financial statements as reductions to sales. The Company’s net sales represent gross sales invoiced to customers, less certain related charges for discounts, returns, rebates, charge-backs and other allowances. Cost of sales includes the cost of raw materials and all labor and overhead associated with the manufacturing and packaging of the products. Gross margins are affected by, among other things, changes in the relative sales mix among our products and valuation and/or charge off of slow moving, expired or obsolete inventories. To perform revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps:     ● identification of the promised goods or services in the contract;   ● determination of whether the promised goods or serves are performance obligations including whether they are distinct in the context of the contract;   ● measurement of the transaction price, including the constraint on variable consideration;   ● allocation of the transaction price to the performance obligations based on estimated selling prices; and   ● recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise to transfer a distinct good or service to the customer and is the unit of account in ASC 606.
Cost of Goods, Shipping and Handling Costs [Policy Text Block]	Shipping and Handling Costs. Shipping and handling costs were approximately $1,006 and $349 for the fiscal years ended June 30, 2023 and 2022, respectively, and are included in cost of sales in the accompanying Consolidated Statements of Operations.
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation. The Company has two stock-based compensation plans that have outstanding options issued in accordance with such plans. The Company periodically grants stock options to employees and directors in accordance with the provisions of its stock option plans, with the exercise price of the stock options being set at the closing market price of the common stock on the date of grant. Stock based compensation expense is recognized based on the estimated fair value, utilizing a Black-Scholes option pricing model, of the instrument on the date of grant over the requisite vesting period, which is generally three years.
Income Tax, Policy [Policy Text Block]	Income Taxes. The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will not be realized.   The Company files a U.S. federal income tax return as well as returns for various states. The Company’s income taxes have not been examined by any tax authorities for the periods subject to review by such taxing authorities, except for the State of New Jersey tax filings for MDC and CII which were reviewed by the State of New Jersey for the then open tax periods of 2014 through 2017 and 2016 to 2019, respectively.  Uncertain tax positions, if any, taken on our tax returns are accounted for as liabilities for unrecognized tax benefits. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the Consolidated Statements of Operations. There were no liabilities recorded for uncertain tax positions at June 30, 2023 or 2022.
Lessee, Leases [Policy Text Block]	Leases. We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities on our consolidated balance sheets.   The ROU assets related to Finance leases are included in property and equipment on our consolidated statement of financial condition.    Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.   We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component.
Earnings Per Share, Policy [Policy Text Block]	Earnings Per Share. Basic earnings per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, subject to anti-dilution limitations using the treasury stock method.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments. Generally accepted accounting principles require disclosing the fair value of financial instruments to the extent practicable for financial instruments which are recognized or unrecognized in the balance sheet. The fair value of the financial instruments disclosed herein is not necessarily representative of the amount that could be realized or settled, nor does the fair value amount consider the tax consequences of realization or settlement.   In assessing the fair value of financial instruments, the Company uses a variety of methods and assumptions, which are based on estimates of market conditions and risks existing at the time. For certain instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, it was estimated that the carrying amount approximated fair value because of the short maturities of these instruments. All debt is based on current rates at which the Company could borrow funds with similar remaining maturities and approximates fair value.
Loans and Leases Receivable, Allowance for Loan Losses Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts. In the normal course of business, the Company extends credit to customers. Accounts receivable, less the allowance for doubtful accounts, reflect the net realizable value of receivables, and approximate fair value. The Company believes there is no concentration of credit risk with any single customer whose failure or nonperformance would materially affect the Company’s results other than as discussed in Note 9(c) – Significant Risks and Uncertainties – Major Customers. On a regular basis, the Company evaluates its accounts receivables and establishes an allowance for doubtful accounts based on a combination of specific customer circumstances, credit conditions, and historical write-offs and collections. The allowance for doubtful accounts as of June 30, 2023 and 2022 was $37 and $85, respectively. Accounts receivable are charged off against the allowance after management determines that the potential for recovery is remote.
Inventory, Policy [Policy Text Block]	Inventories. Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. Allowances for obsolete and overstock inventories are estimated based on “expiration dating” of inventory and projection of sales.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment. Property and equipment are recorded at cost and are depreciated using the straight line method over the following estimated useful lives:   Building 15 Years Leasehold Improvements    Shorter of estimated useful life or term of lease Machinery and Equipment   7 Years Transportation Equipment 5 Years
Goodwill and Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets. Long-lived assets are reviewed for impairment when circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows estimated by the Company to be generated by such assets. If such assets are considered to be impaired, the impairment to be recognized is the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of by sale are recorded as held for sale at the lower of carrying value or estimated net realizable value. Tests for impairment or recoverability are performed at least annually and require significant management judgment and the use of estimates which the Company believes are reasonable and appropriate at the time of the impairment test. Future unanticipated events affecting cash flows and changes in market conditions could affect such estimates and result in the need for an impairment charge. The Company also re-evaluates the periods of amortization to determine whether circumstances warrant revised estimates of current useful lives. No impairment losses were identified or recorded in the fiscal years ended June 30, 2023 and 2022 on the Company’s long-lived assets.
Investment, Policy [Policy Text Block]	Investment in iBio, Inc. Prior to the adoption of ASU 2016-01 on July 1, 2018, the Company accounted for its investment in iBio, Inc. (“iBio”) common stock on the cost basis as it retained approximately 6% of its interest in iBio (the “iBio Stock”) at the time of the spin-off of this subsidiary in August 2008.  The Company reviewed its investment in iBio for impairment and recorded a loss when there was deemed to be a permanent impairment of the investment.  To date, there were cumulative impairment charges of approximately $2,562. ASU 2016-01, requires equity investments to be measured at fair value and recognize changes in fair value in net income.  During the year ended June 30, 2023 and 2022, the Company recognized realized losses of $35 and $0, respectively and unrealized gain (loss) of $27 and $(55) for the fiscal years ended June 30, 2023 and 2022, respectively.  As of June 30, 2023, the Company no longer owns any iBio Stock and as of June 3, 2022, the market value of the iBio Stock was approximately $12, based on the trade price at the close of trading on June 30, 2022.  The investment in iBio is included in other current assets in the consolidated balance sheets as of June 30, 2022 at the respective market value.
New Accounting Pronouncements, Policy [Policy Text Block]	Accounting Pronouncements Adopted   In June 2016, the FASB issued ASU 2016-13 “Financial Instruments-Credit Losses-Measurement of Credit Losses on Financial Instruments”. This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance applies to loans, accounts receivable, trade receivables and other financial assets measured at amortized cost, loan commitments, debt securities and beneficial interests in securitized financial assets, but the effect on the Company is projected to be limited to accounts receivable. The guidance was effective for the fiscal year beginning on July 1, 2023, including interim periods within that year. The adoption of this standard did not have a material impact on the Company’s Consolidated Financial Statements.   In May 2019, the FASB issued ASU 2021-05 “Financial Instruments-Credit Losses (Topic 326)” which provides transition relief for companies adopting ASU 2016-13. This guidance amends ASU 2016-13 to allow companies to elect, upon adoption of ASU 2016-13, the fair value option on financial instruments that were previously recorded at amortized cost under certain circumstances. Companies are required to make this election on and instrument by instrument basis. The guidance will be effective for the fiscal year beginning on July 1, 2023, including interim periods within that year. The adoption of this standard did  not have a material impact on the Company’s Consolidated Financial Statements.     In October 2021, the FASB issued ASU 2021-10, Codification Improvements.  The guidance contains improvements to the Codification by ensuring that all guidance that requires or provides an option or an entity to provide information in the notes to the financial statements is codified in the Disclosure Section of the Codification.  The guidance also contains Codifications that are varied in nature and may affect the application of the guidance in cases in which the original guidance may have been unclear.  For public business entities, the amendments in the ASU are effective for annual periods beginning after December 15, 2022, and interim periods within annual periods beginning after December 15, 2023.  The adoption of ASU 2021-10 did not have a material impact on its consolidated financial statements.

v3.23.2

Note 3 - Inventories (Tables)	12 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30,       2023     2022                     Raw materials   $ 6,859     $ 7,586   Work-in-process     2,148       1,759   Finished goods     1,254       1,440   Total   $ 10,261     $ 11,055

v3.23.2

Note 4 - Property and Equipment, Net (Tables)	12 Months Ended
	Jun. 30, 2023
Notes Tables
Property, Plant and Equipment [Table Text Block]	June 30,       2023     2022                     Land and building   $ 1,250     $ 1,250   Leasehold improvements     1,371       1,371   Machinery and equipment     6,801       6,727   Transportation equipment     -       6         9,422       9,354   Less:  Accumulated depreciation and amortization     (7,769 )     (7,444 ) Total   $ 1,653     $ 1,910

v3.23.2

Note 5 - Senior Credit Facility and Other Long Term Debt (Tables)	12 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Debt [Table Text Block]	Principal Amount     Interest Rate   Maturity Date     June 30,                 2023     2022             Revolving advances under Senior Credit Facility with PNC Bank, National Association   $ -     $ 101       8.25 % 5/15/2024 Total outstanding debt   $ -     $ 101

v3.23.2

Note 6 - Interest Expense (Tables)	12 Months Ended
	Jun. 30, 2023
Notes Tables
Interest Expense Disclosure Table [Table Text Block]	For the Fiscal Year Ended June 30,       2023     2022                     Interest on Senior Debt   $ 40     $ 103   Amortization of prepaid financing costs     12       21   Other interest expense     -       4   Interest Expense   $ 52     $ 128

v3.23.2

Note 7 - Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	For the fiscal year       ended June 30,       2023     2022                     Current - Federal tax expense   $ (110 )   $ (600 ) Current - State tax expense     (61 )     (289 ) Deferred - Federal benefit     55       2,106   Deferred - State tax (expense) benefit     (18 )     24   Income tax (expense) benefit, net   $ (134 )   $ 1,241
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	For the fiscal year       ended June 30,       2023     2022   Statutory federal income tax rate     (21.0 )%     (21.0 )% State income tax rate     (55.1 )%     (11.5 )% Stock compensation     (166.0 )%     (4.6 )% Change in valuation allowance     201.2 %     85.6 % Other temporary differences     (62.1 )%     (0.6 )% Loss on sale of iBio Stock     (18.4 )%     -   Non-deductible expenses     (12.6 )%     (0.1 )% Effective income tax rate     (134 )%     47.8 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	June 30,       2023     2022   Deferred Tax Assets                 Net operating loss   $ 5,105     $ 5,166   Capital loss carryover     678       485   Depreciation     (139 )     (157 ) Inventory     180       149   Other     337       296   Valuation allowance     (1,435 )     (1,141 ) Total deferred tax asset, net   $ 4,726     $ 4,798

v3.23.2

Note 10 - Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2023
Notes Tables
Lease, Cost [Table Text Block]	2023     2022       Related Party - Vitamin Realty     Other Leases     Totals     Related Party - Vitamin Realty     Other Leases     Totals                                                     Operating Lease Costs   $ 842     $ 88     $ 650     $ 566     $ 84     $ 650                                                     Finance Operating Lease Costs:                                                 Amortization of right-of use assets   $ -     $ 12     $ 12     $ -     $ 3     $ 3   Total Finance Lease Costs   $ -     $ 12     $ 12     $ -     $ 3     $ 3
Leases and Remaining Commitments [Table Text Block]	Right-of-use Assets     Current Portion Operating Lease Obligations     Operating Lease Obligations     Remaining Cash Commitment                                     Vitamin Realty Leases   $ 2,061     $ 772     $ 1,289     $ 1,972   Warehouse Lease     541       108       433       631   Office equipment leases     21       8       13       23       $ 2,623     $ 888     $ 1,735     $ 2,830       Right-of-use Assets     Current Portion Operating Lease Obligations     Operating Lease Obligations     Remaining Cash Commitment                                     Vitamin Realty Leases   $ 1,839     $ 503     $ 1,338     $ 1,972   Office equipment leases     28       7       21       32       $ 1,867     $ 510     $ 1,359     $ 2,004
Supplemental Cash Flow Information, Leases [Table Text Block]	Related Party - Vitamin Realty     Other Leases     Totals                             Cash paid for amounts included in the measurement of lease liabilities:                                                   Operating cash flows from operating leases   $ 842     $ 147     $ 989   Operating cash flows from finance lease obligations     -       -       -   Financing cash flows from finance lease obligations     -       35       35       Related Party - Vitamin Realty     Other Leases     Totals                             Cash paid for amounts included in the measurement of lease liabilities:                                                   Operating cash flows from operating leases   $ 566     $ 84     $ 650   Operating cash flows from finance lease obligations     -       -       -   Financing cash flows from finance lease obligations     -       -       -
Lessee, Operating Lease and Finance Lease, Liability, Maturity [Table Text Block]	Year ending June 30,   Operating Lease Commitment     Related Party Operating Lease Commitment     Finance Lease Obligation     Total                                     2024   $ 146     $ 842     $ 42     $ 1,030   2025     149       842       7       998   2026     148       492       -       640   2027     148       -       -       148   2028     63       -       -       63   Total minimum lease payments     654       2,176       49       2,879   Imputed interest     (92 )     (115 )     -       (207 ) Total   $ 562     $ 2,061     $ 49     $ 2,672

v3.23.2

Note 12 - Equity Transactions and Stock-based Compensation (Tables)	12 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Risk Free Interest Rate     3.85% to 3.00 % Volatility     103.3% to 116.9 % Term     4.5 to 7.5 years   Dividend Rate     0.00 % Closing Price of Common Stock   $ 0.41
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted               Average               Exercise       Options     Price                     Outstanding as of July 1, 2021     3,916,666     $ 0.26   Granted     764,700       0.85   Exercised     (146,333 )     0.23   Terminated     (44,700 )     0.53   Expired     (46,400 )     0.47   Outstanding as of June 30, 2022     4,443,933       0.36   Granted     527,000       0.42   Exercised     -       -   Terminated     -       -   Expired     (594,649 )     0.46   Outstanding as of June 30, 2023     4,376,284     $ 0.35                     Exercisable at June 30, 2022     3,524,500     $ 0.26   Exercisable at June 30, 2023     3,626,551     $ 0.30
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Weighted                     Weighted   Weighted Average       Average             Average   Remaining       Exercise   Range of Exercise Price   Outstanding   Exercise Price   Contractual Life (years) Exercisable   Price                                         $ 0.09 - $ 0.10     1,221,000   $ 0.09   1.9   1,296,000   $ 0.09   $ 0.21 - $ 0.21     1,194,000     0.21   5.9   1,209,000     0.21   $ 0.23 - $ 0.25     250,000     0.23   3.4   250,000     0.23   $ 0.41 - $ 0.41     426,500     0.41   9.4   -     0.00   $ 0.51 - $ 0.51     200,000     0.51   9.0   200,000     0.51   $ 0.65 - $ 0.65     570,667     0.65   7.4   431,000     0.65   $ 0.72 - $ 0.72     66,667     0.72   0.7   66,667     0.72   $ 0.95 - $ 0.95     425,783     0.95   8.4   242,217     0.95   $ 1.05 - $ 1.05     21,667     1.05   0.7   21,667     1.05   $ 0.09 - $ 1.05     4,376,284   $ 0.35   7.0   3,626,551   $ 0.30

v3.23.2

Note 13 - Segment Information (Tables)	12 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Sales, Net     Segment                                 U.S.     International             Gross             Capital     Total         Customers     Customers     Total     Profit     Depreciation     Expenditures     Assets   Contract Manufacturing 2023   $ 40,230     $ 8,047     $ 48,277     $ 3,630     $ 348     $ 109     $ 19,507     2022     44,450       9,641       54,091       5,917       332       486       19,061                                                               Other Nutraceutical Businesses 2023     2,387       8       2,395       431       3       7       5,924     2022     2,067       88       2,155       635       4       -       6,189                                                               Total Company 2023     42,617       8,055       50,672       4,061       351       116       25,431     2022     46,517       9,729       56,246       6,552       336       486       25,250

v3.23.2

Note 1 - Business (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Revenue from Contract with Customer, Including Assessed Tax	$ 50,672	$ 56,246
Branded Products [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 0	$ 0

v3.23.2

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended				24 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2023	Aug. 31, 2008
Cost of Goods and Services Sold	$ 46,611	$ 49,694
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		3 years
Liability for Uncertainty in Income Taxes, Current			$ 0
Accounts Receivable, Allowance for Credit Loss	37	$ 85			$ 37
Impairment of Intangible Assets, Finite-Lived			$ 0
Cost Method Investment, Ownership Percentage						6.00%
Asset Impairment Charges, Total		2,562
Realized Investment Gains (Losses)	(35)	0
Unrealized Gain (Loss) on Investments	$ 27	(55)
Investment Owned, at Fair Value		$ 12
Building and Building Improvements [Member]
Property, Plant and Equipment, Useful Life (Year)		15 years
Machinery and Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)		7 years
Air Transportation Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)		5 years
State and Local Jurisdiction [Member] | New Jersey Division of Taxation [Member] | MDC [Member]
Income Tax Examination, Year under Examination		2014
State and Local Jurisdiction [Member] | New Jersey Division of Taxation [Member] | CII [Member]
Income Tax Examination, Year under Examination		2016		2016 2017 2018 2019
Shipping and Handling [Member]
Cost of Goods and Services Sold		$ 349			$ 1,006

v3.23.2

Note 3 - Inventories - Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Raw materials	$ 6,859	$ 7,586
Work-in-process	2,148	1,759
Finished goods	1,254	1,440
Total	$ 10,261	$ 11,055

v3.23.2

Note 4 - Property and Equipment, Net (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Depreciation	$ 351	$ 336
Gain (Loss) on Disposition of Property Plant Equipment	1	22
Fully Depreciated Property [Member]
Property, Plant and Equipment, Disposals	26	309
Gain (Loss) on Disposition of Property Plant Equipment	0	2
Property Not Fully Depreciated [Member]
Property, Plant and Equipment, Disposals	0	16
Equipment [Member]
Gain (Loss) on Disposition of Property Plant Equipment	$ 1	$ 20

v3.23.2

Note 4 - Property and Equipment, Net - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Property and equipment, gross	$ 9,422	$ 9,354
Less: Accumulated depreciation and amortization	(7,769)	(7,444)
Total	1,653	1,910
Land and Building [Member]
Property and equipment, gross	1,250	1,250
Leasehold Improvements [Member]
Property and equipment, gross	1,371	1,371
Machinery and Equipment [Member]
Property and equipment, gross	6,801	6,727
Transportation Equipment [Member]
Property and equipment, gross	$ 0	$ 6

v3.23.2

Note 5 - Senior Credit Facility and Other Long Term Debt (Details Textual) $ in Thousands		3 Months Ended	12 Months Ended
	May 15, 2019 USD ($)	Mar. 31, 2023	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	May 11, 2023
Proceeds from Sale, Maturity and Collection of Investments, Total			$ 4	$ 0
iBio Stock [Member]
Proceeds from Sale, Maturity and Collection of Investments, Total					$ 96
Amended Loan Agreement [Member]
Senior Notes, Total	$ 11,585
Debt Instrument, Debt Default, Interest Rate Basic Spread	2.00%
Line of Credit Facility Covenant Prepayment Provisions Percentage of Excess Cash flow					25.00%
Amended Loan Agreement [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate		0.10%
Amended Loan Agreement [Member] | Term Loan [Member]
Debt Instrument, Face Amount	$ 3,585
Line of Credit Facility, Interest Rate at Period End				5.00%
Number of Consecutive Monthly Installments	84
Number of Consecutive Monthly Installments, Fixed Amount	83
Debt Instrument, Periodic Payment, Total	$ 43
Line of Credit Facility Covenant Prepayment Provisions Percentage of Excess Cash flow	25.00%
Amended Loan Agreement [Member] | Term Loan [Member] | Eurodollar [Member]
Debt Instrument, Basis Spread on Variable Rate	3.00%
Amended Loan Agreement [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 8,000
Line of Credit Facility, Interest Rate at Period End			8.25%	4.75%		8.50%
Line of Credit Facility Covenant Maximum Aggregate Revolving Advance	$ 8,000
Line of Credit Facility Covenant Aggregate Revolving Advance Receivables Advance Rate	85.00%
Line of Credit Facility Covenant Aggregate Revolving Advance Inventory Advance Rate	75.00%
Line of Credit Facility, Covenan,t Aggregate Revolving Advance, Appraised Liquidation Value, Inventory Advance Rate	85.00%
Amended Loan Agreement [Member] | Revolving Credit Facility [Member] | Eurodollar [Member]
Debt Instrument, Basis Spread on Variable Rate	2.50%

v3.23.2

Note 5 - Senior Credit Facility and Other Long Term Debt - Debt Outstanding (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Total outstanding debt	$ 0	$ 101
Revolving Advances [Member]
Notes Payable	$ 0	$ 101
Revolving advances under Senior Credit Facility with PNC Bank, National Association		8.25%

v3.23.2

Note 6 - Interest Expense (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Interest Payable	$ 0	$ 3
Debt Related to Interest Expense [Member]
Debt, Weighted Average Interest Rate	5.67%	3.33%

v3.23.2

Note 6 - Interest Expense - Interest Expense Components (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Amortization of prepaid financing costs	$ 12	$ 21
Other interest expense	0	4
Interest Expense	52	128
Senior Notes [Member]
Interest Expense, Long-Term Debt	$ 40	$ 103

v3.23.2

Note 7 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2020	Jul. 10, 2023	Jun. 30, 2021
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ (18)	$ 24
Liability for Uncertainty in Income Taxes, Current					$ 0
Income Tax Examination, Penalties and Interest Accrued, Total					0
Deferred Tax Assets Related to Net Operating Loss [Member]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	1,795
Capital Loss Carryforward [Member]
Tax Credit Carryforward, Amount				$ 2,343
Capital Loss Carryforward [Member] | Tax Year 2025 [Member]
Tax Credit Carryforward, Amount					271
Capital Loss Carryforward [Member] | Tax Year 2026 [Member]
Tax Credit Carryforward, Amount					1,152
Capital Loss Carryforward [Member] | Tax Year 2028 [Member]
Tax Credit Carryforward, Amount					$ 920
Domestic Tax Authority [Member]
Operating Loss Carryforwards	21,700
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	$ 3,997
State and Local Jurisdiction [Member] | New Jersey Division of Taxation [Member] | CII [Member]
Income Tax Examination, Year under Examination		2016	2016 2017 2018 2019

v3.23.2

Note 7 - Income Taxes - Components of the Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Current - Federal tax expense	$ (110)	$ (600)
Current - State tax expense	(61)	(289)
Deferred - Federal benefit	55	2,106
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	(18)	24
Income tax (expense) benefit, net	$ (134)	$ 1,241

v3.23.2

Note 7 - Income Taxes - Reconciliation of the Statutory Tax Rate to the Effective Tax Rate (Details)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Statutory federal income tax rate	(21.00%)	(21.00%)
State income tax rate	(55.10%)	(11.50%)
Stock compensation	166.00%	4.60%
Change in valuation allowance	201.20%	85.60%
Other temporary differences	(62.10%)	(0.60%)
Loss on sale of iBio Stock	(18.40%)	0.00%
Non-deductible expenses	(12.60%)	(0.10%)
Effective income tax rate	(134.00%)	47.80%

v3.23.2

Note 7 - Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Net operating loss	$ 5,105	$ 5,166
Capital loss carryover	678	485
Depreciation	(139)	(157)
Inventory	180	149
Other	337	296
Valuation allowance	(1,435)	(1,141)
Total deferred tax asset, net	$ 4,726	$ 4,798

v3.23.2

Note 8 - Profit-sharing Plan (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 81	$ 86

v3.23.2

Note 9 - Significant Risks and Uncertainties (Details Textual) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022 USD ($)
Cash, FDIC Insured Amount		$ 250
Cash, Uninsured Amount		$ 1,949
Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Number of Major Customers		2
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Customers [Member]
Concentration Risk, Percentage	89.00%	90.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 1 [Member] | Contract Manufacturing [Member]
Concentration Risk, Percentage	70.00%	67.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 1 [Member] | Other Nutraceutical Business [Member]
Concentration Risk, Percentage	56.00%	40.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 2 [Member] | Contract Manufacturing [Member]
Concentration Risk, Percentage	24.00%	26.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 2 [Member] | Other Nutraceutical Business [Member]
Concentration Risk, Percentage	16.00%	1.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 3 [Member] | Other Nutraceutical Business [Member]
Concentration Risk, Percentage	9.00%	19.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member]
Concentration Risk, Percentage	84.00%	70.00%
Revenue, Segment Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 1 [Member] | Branded Nutraceutical [Member]
Concentration Risk, Percentage	10.00%
Number of Employees, Geographic Area [Member] | Unionized Employees Concentration Risk [Member]
Concentration Risk, Percentage	74.00%

v3.23.2

Note 10 - Commitments and Contingencies (Details Textual)					12 Months Ended
	Jul. 01, 2022 USD ($)	Jun. 15, 2022 USD ($)	May 19, 2014 USD ($) ft²	Jan. 05, 2012 USD ($) ft²	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Aug. 04, 2023 USD ($)	Mar. 31, 2023 USD ($) a	Jul. 15, 2022 ft²	Jan. 04, 2012 ft²
Subsequent Event [Member] | Transportation Equipment [Member]
Lessee, Operating Lease, Term of Contract (Year)							4 years
Lessee, Operating Lease, Liability, Annual Commitment							$ 21
Operating Lease Renewed for Office Space [Member]
Lessee, Operating Lease, Term of Contract (Year)								1 year
Lessee, Operating Lease, Liability, Annual Commitment								$ 10,000
Third Amendment With Vitamin Realty [Member]
Area of Real Estate Property (Square Foot) | a								12,500
Lessee, Operating Lease, Term of Contract (Year)								5 years
Lessee, Operating Lease, Liability, Annual Commitment								$ 134,000
Fifth Year of Finance Lease [Member]
Lessee, Operating Lease, Liability, Annual Commitment								$ 150,000
Unrelated Party [Member]
Operating Lease, Liability					$ 562,000
Lessee, Operating Lease, Discount Rate					4.41%	3.87%
Operating Lease, Weighted Average Remaining Lease Term (Year)					2 years 10 months 24 days	3 years 6 months
Finance Lease, Liability		$ 85,000
Debt Instrument, Periodic Payment, Total		$ 4,000
Debt Instrument, Interest Rate, Stated Percentage		0.00%
Lessee, Finance Lease, Discount Rate					0.00%
Finance Lease, Weighted Average Remaining Lease Term (Year)					1 year 2 months 12 days	2 years 2 months 12 days
Accounts Payable [Member]
Finance Lease, Liability					$ 49,000
Manhattan Drug Company [Member]
Area of Real Estate Property (Square Foot) | ft²				76,161					116,175	74,898
Payments for Rent	$ 842,000			$ 533,000
AgroLabs [Member]
Area of Real Estate Property (Square Foot) | ft²			2,700
Payments for Rent			$ 27,000
Chairman, Chief Executive Office and Major Stockholder [Member]
Percent of Ownership for Warehouse and Office Facilities Leased						100.00%
Vitamin Realty LLC [Member]
Operating Lease, Expense					1,269,000	$ 896,000
Operating Lease, Liability					2,061,000	1,841,000
Vitamin Realty LLC [Member] | Accounts Payable [Member]
Operating Lease, Liability					$ 0	$ 72,000
Minimum [Member]
Lessee, Lease, Term of Contract (Year)					1 year
Maximum [Member]
Lessee, Lease, Term of Contract (Year)					7 years

v3.23.2

Note 10 - Commitments and Contingencies - Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating Lease Costs	$ 650	$ 650
Amortization of right-of use assets	12	3
Total Finance Lease Costs	12	3
Unrelated Party [Member]
Operating Lease Costs	88	84
Amortization of right-of use assets	12	3
Total Finance Lease Costs	12	3
Vitamin Realty LLC [Member]
Operating Lease Costs	842	566
Amortization of right-of use assets	0	0
Total Finance Lease Costs	$ 0	$ 0

v3.23.2

Note 10 - Commitments and Contingencies - Leases and Commitments (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Operating lease right-of-use assets	$ 2,623	$ 1,867
Current portion operating lease obligations	888	510
Operating lease obligations	1,735	1,359
Remaining cash commitment	2,830	2,004
Office Equipment Leases [Member]
Operating lease right-of-use assets	21	28
Current portion operating lease obligations	8	7
Operating lease obligations	13	21
Remaining cash commitment	23	32
Vitamin Realty LLC [Member]
Operating lease right-of-use assets	2,061	1,839
Current portion operating lease obligations	772	503
Operating lease obligations	1,289	1,338
Remaining cash commitment	1,972	$ 1,972
Warehouse Lease [Member]
Operating lease right-of-use assets	541
Current portion operating lease obligations	108
Operating lease obligations	433
Remaining cash commitment	$ 631

v3.23.2

Note 10 - Commitments and Contingencies - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating cash flows from operating leases	$ 989	$ 650
Operating cash flows from finance lease obligations	0	0
Financing cash flows from finance lease obligations	35	0
Unrelated Party [Member]
Operating cash flows from operating leases	147	84
Operating cash flows from finance lease obligations	0	0
Financing cash flows from finance lease obligations	35	0
Vitamin Realty LLC [Member]
Operating cash flows from operating leases	842	566
Operating cash flows from finance lease obligations	0	0
Financing cash flows from finance lease obligations	$ 0	$ 0

v3.23.2

Note 10 - Commitments and Contingencies - Minimum Rental Commitment for Long-term Non-cancelable Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022	Jun. 15, 2022
2024	$ 42
2024	1,030
2025	7
2025	998
2026	0
2026	640
2027	0
2027	148
2028	0
2028	63
Total minimum lease payments, Capital Lease Obligation	49
Total minimum lease payments	2,879
Imputed interest, Capital Lease Obligation	0
Imputed interest	(207)
Total	2,672
Accounts Payable [Member]
Total, Capital Lease Obligation	49
Vitamin Realty LLC [Member]
2024	842
2025	842
2026	492
2027	0
2028	0
Total minimum lease payments, Operating Lease	2,176
Imputed interest, Operating Lease	(115)
Total, Operating Lease	2,061	$ 1,841
Vitamin Realty LLC [Member] | Accounts Payable [Member]
Total, Operating Lease	0	$ 72
Unrelated Party [Member]
2024	146
2025	149
2026	148
2027	148
2028	63
Total minimum lease payments, Operating Lease	654
Imputed interest, Operating Lease	(92)
Total, Operating Lease	$ 562
Total, Capital Lease Obligation			$ 85

v3.23.2

Note 12 - Equity Transactions and Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Jul. 31, 2023	Nov. 30, 2020	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)				6,823,569
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			527,000	764,700
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)			$ 0.09
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)			1.05
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)				3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)			0.35	$ 0.36	$ 0.26
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)			$ 0.42	$ 0.85
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value			$ 461	$ 1,002
Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			764,700
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)			$ 0.51
Maximum [Member] | Director [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)			1.045
Minimum [Member] | Director [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)			$ 0.95
Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)			3 years
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)			4,376,284	537,600
Share-Based Payment Arrangement, Option [Member] | Subsequent Event [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	200,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	1 year
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 0.33
Share-Based Payment Arrangement, Option [Member] | Subsequent Event [Member] | Director [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage	25.00%
Share-Based Payment Arrangement, Option [Member] | Subsequent Event [Member] | Each Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	50,000
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		10 years		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)				3 years
Share-Based Payment Arrangement, Expense				$ 369
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total				$ 480
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				2 years 6 months
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		5 years		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)				1 year
Share-Based Payment Arrangement, Expense			$ 320
Stock Option 2001 Plan [Member]
Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Originally Authorized (in shares)				7,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)				6,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				13,000,000
Stock Option 1997 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				5,000,000
Stock Option 2022 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			538,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			527,000
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)			$ 0.41
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)			$ 0.45

v3.23.2

Note 12 - Equity Transactions and Stock-based Compensation - Fair Value of Stock Option Using Black-Scholes Option Pricing Model (Details)	12 Months Ended
	Jun. 30, 2023 $ / shares
Dividend Rate	0.00%
Closing Price of Common Stock (in dollars per share)	$ 0.41
Minimum [Member]
Risk Free Interest Rate	3.85%
Volatility	103.30%
Maximum [Member]
Risk Free Interest Rate	3.00%
Volatility	116.90%

v3.23.2

Note 12 - Equity Transactions and Stock-based Compensation - Summary of the Company's Stock Option Activity, and Related Information (Details) - $ / shares	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Balance (in shares)	4,443,933	3,916,666
Balance, weighted average exercise price (in dollars per share)	$ 0.36	$ 0.26
Granted (in shares)	527,000	764,700
Granted, weighted average exercise price (in dollars per share)	$ 0.42	$ 0.85
Exercised (in shares)	0	(146,333)
Exercised, weighted average exercise price (in dollars per share)	$ 0	$ 0.23
Terminated (in shares)	0	(44,700)
Terminated, weighted average exercise price (in dollars per share)	$ 0	$ 0.53
Expired (in shares)	(594,649)	(46,400)
Expired, weighted average exercise price (in dollars per share)	$ 0.46	$ 0.47
Balance (in shares)	4,376,284	4,443,933
Balance, weighted average exercise price (in dollars per share)	$ 0.35	$ 0.36
Exercised (in shares)	0	146,333
Terminated (in shares)	0	44,700
Balance (in shares)	4,376,284	4,443,933
Balance, weighted average exercise price (in dollars per share)	$ 0.35	$ 0.36
Exercisable (in shares)	3,626,551	3,524,500
Exercisable, weighted average exercise price (in dollars per share)	$ 0.30	$ 0.26

v3.23.2

Note 12 - Equity Transactions and Stock-based Compensation - Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range (Details) - $ / shares	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Range of Exercise Price, Lower Limit (in dollars per share)	$ 0.09
Range of Exercise Price, Upper Limit (in dollars per share)	$ 1.05
Outstanding (in shares)	4,376,284	4,443,933	3,916,666
Weighted average exercise price (in dollars per share)	$ 0.35	$ 0.36	$ 0.26
Weighted Average Remaining Contractual Life (Year)	7 years
Exercisable (in shares)	3,626,551	3,524,500
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.30	$ 0.26
Range One [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	0.09
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.10
Outstanding (in shares)	1,221,000
Weighted average exercise price (in dollars per share)	$ 0.09
Weighted Average Remaining Contractual Life (Year)	1 year 10 months 24 days
Exercisable (in shares)	1,296,000
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.09
Range Two [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	0.21
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.21
Outstanding (in shares)	1,194,000
Weighted average exercise price (in dollars per share)	$ 0.21
Weighted Average Remaining Contractual Life (Year)	5 years 10 months 24 days
Exercisable (in shares)	1,209,000
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.21
Range Three [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	0.23
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.25
Outstanding (in shares)	250,000
Weighted average exercise price (in dollars per share)	$ 0.23
Weighted Average Remaining Contractual Life (Year)	3 years 4 months 24 days
Exercisable (in shares)	250,000
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.23
Range Four [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	0.41
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.41
Outstanding (in shares)	426,500
Weighted average exercise price (in dollars per share)	$ 0.41
Weighted Average Remaining Contractual Life (Year)	9 years 4 months 24 days
Exercisable (in shares)	0
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.00
Range Five [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	0.51
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.51
Outstanding (in shares)	200,000
Weighted average exercise price (in dollars per share)	$ 0.51
Weighted Average Remaining Contractual Life (Year)	9 years
Exercisable (in shares)	200,000
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.51
Range Six [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	0.65
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.65
Outstanding (in shares)	570,667
Weighted average exercise price (in dollars per share)	$ 0.65
Weighted Average Remaining Contractual Life (Year)	7 years 4 months 24 days
Exercisable (in shares)	431,000
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.65
Range Seven [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	0.72
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.72
Outstanding (in shares)	66,667
Weighted average exercise price (in dollars per share)	$ 0.72
Weighted Average Remaining Contractual Life (Year)	8 months 12 days
Exercisable (in shares)	66,667
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.72
Range Eight [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	0.95
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.95
Outstanding (in shares)	425,783
Weighted average exercise price (in dollars per share)	$ 0.95
Weighted Average Remaining Contractual Life (Year)	8 years 4 months 24 days
Exercisable (in shares)	242,217
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.95
Range Nine [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	1.05
Range of Exercise Price, Upper Limit (in dollars per share)	$ 1.05
Outstanding (in shares)	21,667
Weighted average exercise price (in dollars per share)	$ 1.05
Weighted Average Remaining Contractual Life (Year)	8 months 12 days
Exercisable (in shares)	21,667
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 1.05

v3.23.2

Note 13 - Segment Information (Details Textual)	12 Months Ended
	Jun. 30, 2023 $ / shares	Jun. 30, 2022 $ / shares
Number of Reportable Segments	2
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)	$ 0.46	$ 0.47
Europe and Canada [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)	$ 8,055	$ 9,729

v3.23.2

Note 13 - Segment Information - Operations by Business Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Sales, net	$ 50,672	$ 56,246
Gross Profit	4,061	6,552
Depreciation	351	336
Capital Expenditures	116	486
Assets	25,431	25,250
Contract Manufacturing [Member]
Sales, net	48,277	54,091
Gross Profit	3,630	5,917
Depreciation	348	332
Capital Expenditures	109	486
Assets	19,507	19,061
Other Nutraceutical Business [Member]
Sales, net	2,395	2,155
Gross Profit	431	635
Depreciation	3	4
Capital Expenditures	7	0
Assets	5,924	6,189
UNITED STATES
Sales, net	42,617	46,517
UNITED STATES | Contract Manufacturing [Member]
Sales, net	40,230	44,450
UNITED STATES | Other Nutraceutical Business [Member]
Sales, net	2,387	2,067
Non-US [Member]
Sales, net	8,055	9,729
Non-US [Member] | Contract Manufacturing [Member]
Sales, net	8,047	9,641
Non-US [Member] | Other Nutraceutical Business [Member]
Sales, net	$ 8	$ 88

---